

CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims priority under 35 U.S.C. 119 of Danish applications nos. PA 2002 01719 filed November 8, 2002, PA 2003 00827 filed June 4, 2003 and PA 2003 00734 filed May 14, 2003 and U.S. applications nos. 60/425,642 filed November 12, 2002, 60/476,275 filed June 5, 2003, and 60/xxx,xxx, filed October 31, 2003, the contents of each of which are fully incorporated herein by reference.

FIELD OF THE INVENTION

10 This invention relates to chemical uncouplers with a broader safety window making the use of them in treating obesity and, consequently, in the treatment of obesity related diseases and conditions such as atherosclerosis, hypertension, diabetes, especially type 2 diabetes (NIDDM (non-insulin dependent diabetes mellitus)), diabetic microvascular complica-
15 tion, impaired glucose tolerance, dyslipidemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of cancer such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such as diseases and disorders, which conditions are improved by an increase in mitochondrial respiration, more attractive.

BACKGROUND OF THE INVENTION

20 Obesity is a well-known risk factor for the development of many very common diseases such as atherosclerosis, hypertension, type 2 diabetes (non-insulin dependent diabetes mellitus (NIDDM)), dyslipidemia, coronary heart disease, and osteoarthritis and various malignancies. It also causes considerable problems through reduced motility and decreased quality of life. The incidence of obese people and thereby also these diseases is increasing
25 throughout the entire industrialised world.

The term obesity implies an excess of adipose tissue. In this context obesity is best viewed as any degree of excess adiposity that imparts a health risk. The cut off between normal and obese individuals can only be approximated, but the health risk imparted by the obesity is probably a continuum with increasing adiposity. In the context of the present inven-
30 tion, individuals with a body mass index (BMI = body weight in kilograms divided by the square of the height in meters) above 25 are to be regarded as obese

Even mild obesity increases the risk for premature death and conditions such as diabetes, dyslipidemia, hypertension, atherosclerosis, gallbladder disease and certain types

of cancer. In the industrialised western world the prevalence of obesity has increased significantly in the past few decades. Because of the high prevalence of obesity and its health consequences, its prevention and treatment should be a high public health priority.

Except for exercise, diet and food restriction, which is not feasible for a vast number of patients, no convincing treatment for reducing body weight effectively and acceptably currently exist. However, not only in view of the considerable problems directly related to obesity as described above, but also due to the important effect of obesity as a risk factor in serious and even mortal and common diseases, it is important to find pharmaceutical compounds which are useful in prevention and/or treatment of obesity.

When energy intake exceeds expenditure, the excess calories are stored predominately in adipose tissue, and if this net positive balance is prolonged, obesity results, i.e. there are two components to weight balance, and an abnormality on either side (intake or expenditure) can lead to obesity. This process may be counteracted by increasing the energy expenditure (for instance via exercise) or decreasing the energy intake (for instance by dieting). Pharmacological treatment available up to date only consists of Sibutramine (acting via serotonergic mechanisms, Abbott) and Orlistat (reducing fat uptake from the gut, Roche Pharm) neither reducing body weight effectively nor acceptably. There is therefore a need for pharmaceutical compounds which may be useful in prevention and/or treatment of obesity, for instance by increasing the energy expenditure or decreasing the energy intake.

One way of increasing energy expenditure is by increasing the metabolic rate. Oxidative phosphorylation in mitochondria, the energy from glucose metabolism and free fatty acids oxidation is used to drive the phosphorylation of ADP to ATP. When NADH and FADH₂ formed in the TCA cycle are oxidised back to NAD⁺ and FAD respectively, protons are pumped out of the mitochondrial matrix. The resulting pH gradient (matrix pH~8 and outside pH~7) and potential (~-170 mV, inside negative) across the inner mitochondrial membrane constitute the electrochemical proton gradient. As the effect of a one-unit pH difference corresponds to a potential of 61.5mV, the electrochemical proton gradient exerts a proton-motive force of roughly -230 mV, which is the driving force for the mitochondrial ATP synthesis.

When the ATP consumption thus increases, the cells respond by increasing the ATP synthesis and consequently the inward flux of protons through the ATP synthase, the enzyme responsible for ATP synthesis and thereby the metabolic rate is increased. Chemical uncouplers are compounds, which can transport protons across membranes, and when protons are transported across the inner mitochondrial membrane, the ATP synthase is bypassed. At the (alkaline) matrix side the proton is released and the deprotonated uncoupler

returns to the inter-membrane space where it picks up another proton. The cycling of the uncoupler (or ATP synthesis) and the resulting proton transport leads to an increased outward pumping of protons through an increased oxidation of NADH and FADH₂ by the respiration chain. The NADH concentration in the matrix will consequently drop. Since NADH feed-back
5 inhibits three steps in the TCA cycle (NADH is the main regulator of the TCA cycle), the flux through the TCA cycle will increase. Hence, the metabolic rate will increase.

Compounds, such as chemical uncouplers, which act by increasing the metabolic rate may thus be useful for treating obesity, but also for treating other conditions such as atherosclerosis, hypertension, diabetes, especially type 2 diabetes (NIDDM (non-insulin de-
10 pendent diabetes mellitus)), dyslipidemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of cancer such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such as diseases and disorders, which conditions are improved by a reduced mitochondrial potential.

Furthermore, chemical uncouplers may reduce reactive oxygen species (ROS) that
15 are assumed (De Grey et al, Eur J. Biochem 269, 1995 ff (2002)) to be involved in the aging process, in damage of heart tissue as well as neuronal tissue. It is therefore also possible that conditions affected by ROS may be reversed or halted by intervention by chemical uncouplers. Examples of such conditions include diabetic microvascular diseases in the retina, renal glomerulus and peripheral nerves cell.

20 The best known chemical uncoupler is 2,4-dinitrophenol (DNP), which has been shown to increase energy expenditure in humans as well as animals. The side effects at higher doses include increased perspiration, vasodilatation, skin rashes, cataracts, neuritis and death. Two fatalities amongst the first 100.000 persons treated with DNP, and the fact that the lowest dose, which could be lethal, was only twice the average dose giving a desired
25 50% increase in basal metabolic rate giving a very narrow safety window combined with other factors led to the removal of DNP from the market. Since then no one has attempted to develop or market uncouplers for the treatment of obesity.

DNP is the best known chemical uncoupler; but many other compounds are known to induce uncoupling. DNP derivatives such as 4,6-dinitro-*o*-cresol (Victoria Yellow) and 2,4-
30 dinitro-1-naphtol (Martius Yellow) as well as structurally unrelated compounds such as 2,6-di-*t*-butyl-4-(2',2'-dicyanovinyl)phenol) (SF6847) (also known as 2-(3,5-di-*t*-butyl-4-hydroxybenzylidene)-malononitrile), carbonylcyanide *m*-chlorophenylhydrazone (CCCP) and carbonylcyanide *p*-trifluoromethoxy-phenylhydrazone (FCCP) (Miyoshi H et al. Quantitative relationship between protenophoric and uncoupling activities of analogs of SF6847 (2,6-di-*t*-

butyl-4-(2',2'-dicyanovinyl)phenol), Biochimica et Biophysica Acta 891, 293-299 (1987)) are uncouplers.

Another class of chemical uncouplers is the salicylanilides of which S-13 is the most potent compound discovered so far (Terada H et al. Structural Requirements of Salicylanilides for Uncoupling Activity in Mitochondria Quantitative Analysis of Structure- Uncoupling Relationships, Biochimica et Biophysica Acta 936, 504-512 (1988)).

Goto K et al, Chem. Pharm. Bull. 44(3), 547-551 (1996) describes diethyl 4-[(4-bromo-2-cyanophenyl)carbamoyl]-benzylphosphonate for use as an LPL activator.

T. Shimokawa et al, Drug Development Research 51(1), 43-48 (2000) describes 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-3-methylbenzamide for use as a glucose uptake stimulator.

WO00/06143 to Texas Pharmaceuticals Inc. relates to a method for inducing intracellular hyperthermia comprising a step of administering a mitochondrial uncoupling agent, such as 2,4-dinitrophenol.

US 4,673,691 to Bachynsky relates to the use of 2,4-dinitrophenol for treating obesity.

SUMMARY OF THE INVENTION

The present invention provides a method of using of chemical uncouplers for enhancing mitochondrial respiration, which chemical uncouplers have an acceptably broad safety window making them useful for treating conditions benefiting from an enhancement of mitochondrial respiration, such as obesity, atherosclerosis, hypertension, diabetes, especially type 2 diabetes (NIDDM (non-insulin dependent diabetes mellitus)), dyslipidemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of cancer such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such as diseases and disorders, which conditions are improved by a reduced mitochondrial potential due to a saturation of the uncoupling and thereby the increase of the metabolism.

DESCRIPTION OF THE FIGURES

Figure 1 shows the curve for the stimulation of glucose utilisation caused by SF6847 calculated as a percentage of the stimulation of glucose utilisation caused by DNP according to Assay (I) and how the curve will look for a partial compound according to the present invention. E_{max} is the highest level of stimulation that can be achieved by use if the test com-

pound measured in percentages of the highest level of stimulation achieved by DNP. M is the molar concentration of test compound.

Figure 2 shows how the calculation of EC_{50} in Assay (I) is performed, exemplified by DNP and a test compound according to the present invention. E_{max} is the highest stimulation of glucose utilisation achieved by the test compound and EC_{50} is the concentration of test compound that gives a 50% stimulation.

Figure 3 shows how the glucose utilisation depends on the concentration of the compound for 1) a compound with a decline in efficacy at concentrations slightly above the concentration at which E_{max} is achieved (CE_{max}) and for 2) a compound with no decline in glucose utilisation at concentrations ranging from the concentration at which E_{max} is achieved (CE_{max}). See also Table 1.

DEFINITIONS

The term "alkyl" as used herein, alone or in combination, refers to a straight or branched chain saturated monovalent hydrocarbon radical having from one to twelve carbon atoms, also denoted as C_{1-12} -alkyl. Typical alkyl groups are alkyl groups with from one to eight or from one to six carbon atoms, also denoted as C_{1-8} -alkyl and C_{1-6} -alkyl respectively. Typical C_{1-6} -alkyl groups include, but are not limited to e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, 2-methylbutyl, 3-methylbutyl, 4-methylpentyl, n-pentyl, n-hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl (neopentyl), 1,2,2-trimethylpropyl and the like, while typical C_{1-8} -alkyl groups include the same groups as well as alkyl groups having seven or eight carbon atoms, such as heptyl, octyl, 2,2-dimethylhexyl and the like. The term " C_{1-6} -alkyl" as used herein also includes secondary C_{3-6} -alkyl and tertiary C_{4-6} -alkyl. The term " C_{1-8} -alkyl" as used herein also includes secondary C_{3-8} -alkyl and tertiary C_{4-8} -alkyl. The term " C_{1-12} -alkyl" as used herein also includes secondary C_{3-12} -alkyl and tertiary C_{4-12} -alkyl.

The term "alkenylene" as used herein, alone or in combination, refers to a straight or branched chain divalent hydrocarbon radical having from two to six carbon atoms and at least one carbon-carbon double bond, for example $C_{(3-5)}$ -alkenylene. Typical $C_{(3-5)}$ -alkenylene groups include, but are not limited to, propene-1,3-diyl, 1,3 butadiene-1,4-diyl, and the like. The term "conjugated alkenylene" as used herein, alone or in combination, refers to an alkenylene having consecutive double bonds, such as for instance 1,3 butadiene-1,4-diyl.

The term "cycloalkyl" as used herein, alone or in combination, refers to a non-aromatic carbocyclic monovalent hydrocarbon radical having from three to twelve carbon at-

oms, for example C₃₋₈-cycloalkyl. Such a ring may be optionally fused to one or more other cycloalkyl ring(s). Typical C₃₋₈-cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.

5 The term "aryl" as used herein, alone or in combination, refers to a carbocyclic aromatic ring radical or to a fused aromatic ring system radical, comprising at least one aromatic ring. Typical aryl groups include, but are not limited to, for example phenyl, biphenyl, naphthyl, and the like.

10 The term "heteroaryl", as used herein, alone or in combination, refers to an aromatic ring radical with for instance 5 to 7 member atoms, or to a fused aromatic ring system radical comprising at least one heteroaromatic ring with for instance from 7 to 18 member atoms, containing one or more heteroatoms selected from nitrogen, oxygen, or sulfur heteroatoms, wherein N-oxides and sulfur monoxides and sulfur dioxides are permissible heteroaromatic substitutions; such as e.g. furanyl, thienyl, thiophenyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothiophenyl, indolyl, and indazolyl, and the like.

Examples of "aryl" and "heteroaryl" includes phenyl, biphenyl, indenyl, fluorene, naphthyl (1-naphthyl, 2-naphthyl), anthracenyl (1-anthracenyl, 2-anthracenyl, 3-anthracenyl), thienyl (2-thienyl, 3-thienyl), furanyl (2-furanyl, 3-furanyl), indolyl, oxadiazolyl, isoxazolyl, 20 thiadiazolyl, oxatriazolyl, thiatriazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl, acridinyl, thiazolyl, pyrrolyl (1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), pyrazolyl (1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl), imidazolyl (1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1,2,3-triazol-1-yl, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (isoxazo-3-yl, 25 isoxazo-4-yl, isoxazo-5-yl), isothiazolyl (isothiazo-3-yl, isothiazo-4-yl, isothiazo-5-yl), thiazolyl (2-thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridinyl (2-pyridinyl, 3-pyridinyl, 4-pyridinyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl), pyrazinyl, pyridazinyl (3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl), quinolinyl (2-quinolinyl, 3-quinolinyl, 4-quinolinyl, 5-quinolinyl, 6-quinolinyl, 7-quinolinyl, 8-quinolinyl), isoquinolinyl (1-isoquinolinyl, 3-isoquinolinyl, 4-isoquinolinyl, 5-isoquinolinyl, 6-isoquinolinyl, 7-isoquinolinyl, 8-isoquinolinyl), benzo[b]furanyl (2-benzo[b]furanyl, 3-benzo[b]furanyl, 4-benzo[b]furanyl, 5-benzo[b]furanyl, 6-benzo[b]furanyl, 7-benzo[b]furanyl), 2,3-dihydrobenzo[b]furanyl (2-(2,3-dihydrobenzo[b]furanyl), 3-(2,3-dihydrobenzo[b]furanyl), 4-(2,3-dihydrobenzo[b]furanyl), 5-(2,3-dihydrobenzo[b]furanyl), 6-(2,3-dihydrobenzo[b]furanyl), 7-(2,3-dihydrobenzo[b]furanyl)), benzo[b]thiophenyl (benzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, benzo[b]thiophen-4-yl, 35

benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl), 2,3-dihydro-benzo[b]thiophenyl (2,3-dihydro-benzo[b]thiophen-2-yl, 2,3-dihydrobenzo[b]thiophen-3-yl, 2,3-dihydro-benzo[b]thiophen-4-yl, 2,3-dihydro-benzo[b]thiophen-5-yl, 2,3-dihydro-benzo[b]thiophen-6-yl, 2,3-dihydro-benzo[b]thiophen-7-yl), indolyl (1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), indazolyl (1-indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), benzimidazolyl (1-benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl, 6-benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (2-benzoxazolyl, 3-benzoxazolyl, 4-benzoxazolyl, 5-benzoxazolyl, 6-benzoxazolyl, 7-benzoxazolyl), benzothiazolyl (2-benzothiazolyl, 4-benzothiazolyl, 5-benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), carbazolyl (1-carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl), 5H-dibenz[b,f]azepinyl (5H-dibenz[b,f]azepin-1-yl, 5H-dibenz[b,f]azepine-2-yl, 5H-dibenz[b,f]azepine-3-yl, 5H-dibenz[b,f]azepine-4-yl, 5H-dibenz[b,f]azepine-5-yl), 10,11-dihydro-5H-dibenz[b,f]azepinyl (10,11-dihydro-5H-dibenz[b,f]azepine-1-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-2-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-3-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-4-yl, 10,11-dihydro-5H-dibenz[b,f]azepine-5-yl), benzo[1,3]dioxole (2-benzo[1,3]dioxole, 4-benzo[1,3]dioxole, 5-benzo[1,3]dioxole, 6-benzo[1,3]dioxole, 7-benzo[1,3]dioxole), and tetrazolyl (5-tetrazolyl, N-tetrazolyl) as well as partly or fully saturated analogues of the ring systems mentioned above.

The term "fused aromatic ring system" as used herein, alone or in combination, refers to a carbocyclic aromatic ring radical fused to another carbocyclic aromatic ring radical, the two having two atoms in common. Typical fused aromatic ring systems include, but are not limited to naphthalene, quinoline, isoquinoline, indole, and isoindole.

A radical such as C_{x-y}-cycloalkyl-C_{a-b}-alkyl- shall designate that the radical's point of attachment is in part of the radical mentioned last.

As used herein, the term "optionally" means that the subsequently described event(s) may or may not occur, and includes both event(s) which occur and events that do not occur.

As used herein, the term "substituted" refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.

Certain of the above defined terms may occur more than once in a given structural formulae, and upon such occurrence each term shall be defined independently of the other.

The term "nitro" shall mean the radical -NO₂.

The term "cyano" shall mean the radical -CN.

The term "halogen" shall mean -Cl, -F, -Br or -I..

As used herein, the term "solvate" is a complex of variable stoichiometry formed by a solute (in this case, a compound according to the present invention) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Solvents may be, by way of example, water, ethanol, or acetic acid.

5 As used herein, the term "prodrug" includes biohydrolyzable amides and biohydrolyzable esters and also encompasses a) compounds in which the biohydrolyzable functionality in such a prodrug is encompassed in the compound according to the present invention, and b) compounds which may be oxidized or reduced biologically at a given functional group to yield drug substances according to the present invention. Examples of these functional
10 groups include, but are not limited to, 1,4-dihydropyridine, N-alkylcarbonyl-1,4-dihydropyridine, 1,4-cyclohexadiene, tert-butyl, and the like.

A "therapeutically effective amount" of a compound as used herein means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective amount". Effective amounts for each purpose will depend on the severity
15 of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix.

The term "treatment" and "treating" as used herein means the management and
20 care of a patient for the purpose of combating a condition, such as a disease or a disorder. The term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease,
25 disorder or condition as well as to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications. The patient to be treated is preferably a mammal, in particular a human being.

30 The term "partial compound" as used herein is intended to indicate a compound with an E_{\max} as defined in assay I of less than 75% of that of FCCP, e.g. less than 70%, e.g. less than 65%, e.g. less than 60%, e.g. less than 55%, e.g. less than 50%, e.g. less than 45%, e.g. less than 40%, e.g. less than 35%, e.g. less than 30%, e.g. less than 25%, e.g. less than 20%, e.g. less than 15%, e.g. less than 10%.

DESCRIPTION OF THE INVENTION

The present invention provides a method of using chemical uncouplers for enhancing mitochondrial respiration, which chemical uncouplers have an acceptably broad safety window.

5 More specifically, the present invention provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 75% of the E_{\max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazone in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for increasing mitochondrial respiration.

In a further embodiment, the present invention provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40%, such as less than 35%, for instance less than 30%, such as less than 25%, for instance less than 20%, such as less than 15%, for instance less than 10% of the E_{\max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazone in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for increasing mitochondrial respiration.

The present invention also provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 75% of the E_{\max} of 2,4-dinitrophenol (DNP) in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for increasing mitochondrial respiration.

In a further embodiment, the present invention provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40%, such as less than 35%, for instance less than 30%, such as less than 25%, for instance less than 20%, such as less than 15%, for instance less than 10% of the E_{\max} of 2,4-dinitrophenol in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for increasing mitochondrial respiration.

The E_{\max} of the compounds, FCCP and DNP is calculated as described below under the heading "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

The present invention also provides the use of a chemical compound with a slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

wherein

Y_0 is the degree of stimulation measured as counts per minute (cpm) in Assay (I) in control samples without added test compound,

Y_1 is the degree of stimulation measured as cpm in Assay (I) with added test compound in a concentration of either $EC_{50}/2$ or $EC_{50}/3$,

5 Y_2 is the degree of stimulation measured as cpm in Assay (I) with added test compound in concentration of either $2 \times EC_{50}$ or $3 \times EC_{50}$,

X is 2 or 3 depending on which concentration of Y_1 and Y_2 used, and

n is the slope.

of a value equal to or less than the value for the slope calculated from the above
10 equation with FCCP as test compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for increasing mitochondrial respiration. In a further embodiment, said slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said slope calculated for FCCP.

15 The equation should be understood such that when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/2$, then Y_2 is the degree of stimulation with added test compound in concentration of $2 \times EC_{50}$, and X is 2, and when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/3$, then Y_2 is the degree of stimulation with added test compound in a concentration of $3 \times EC_{50}$, and X is 3.

20 The values for use in the equation is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

In a further embodiment, the slope is calculated by use of the computer software GraphPad Prism 3.0 (GraphPad software, Inc.).

In a further embodiment, the value for the slope calculated from the equation
25
$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

is significantly less than the value for the slope calculated with FCCP as test compound in Assay (I).

The present invention also provides for the use of a compound with a Hill slope, n , calculated as describes in Assay IV herein which is lower than or equal to the Hill slope calculated for FCCP, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for increasing mitochondrial respiration. In a further embodiment, said Hill slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said Hill slope calculated for FCCP.
30

The present invention also provides the use of a compound for which the value for the glucose utilisation caused by the compound in Assay (I) in concentrations of from CE_{max} to ten times CE_{max} does not fall significantly below the value of E_{max} for the compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for increasing mitochondrial respiration. CE_{max} is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

Increasing the mitochondrial respiration as described above may take place *in vitro* or *in vivo*, for instance in an assay or in a subject.

The present invention also provides the use of a chemical compound with an E_{max} in Assay (I), as described in the specification, of less than 75% of the E_{max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazone in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a condition benefiting from an increase in mitochondrial respiration in a patient in need thereof.

In a further embodiment, the present invention provides the use of a chemical compound with an E_{max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40% of the E_{max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazone in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a condition benefiting from an increase in mitochondrial respiration in a patient in need thereof.

The present invention also provides the use of a chemical compound with an E_{max} in Assay (I), as described in the specification, of less than 75% of the E_{max} of 2,4-dinitrophenol in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a condition benefiting from an increase in mitochondrial respiration in a patient in need thereof.

In a further embodiment, the present invention provides the use of a chemical compound with an E_{max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40% of the E_{max} of 2,4-dinitrophenol in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a condition benefiting from an increase in mitochondrial respiration in a patient in need thereof.

The E_{max} of the compounds, FCCP and DNP is calculated as described above.

The present invention also provides the use of a chemical compound with a slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

wherein

Y_0 is the degree of stimulation measured as counts per minute (cpm) in Assay (I) in control samples without added test compound,

Y_1 is the degree of stimulation measured as cpm in Assay (I) with added test compound in a concentration of either $EC_{50}/2$ or $EC_{50}/3$,

5 Y_2 is the degree of stimulation measured as cpm in Assay (I) with added test compound in concentration of either $2 \times EC_{50}$ or $3 \times EC_{50}$,

X is 2 or 3 depending on which concentration of Y_1 and Y_2 used, and

n is the slope.

of a value equal to or less than the value for the slope calculated from the above
10 equation with FCCP as test compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a condition benefiting from an increase in mitochondrial respiration in a patient in need thereof. In a further embodiment, said slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said
15 slope calculated for FCCP.

The equation should be understood such that when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/2$, then Y_2 is the degree of stimulation with added test compound in concentration of $2 \times EC_{50}$, and X is 2, and when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/3$, then Y_2 is the degree of
20 stimulation with added test compound in a concentration of $3 \times EC_{50}$, and X is 3.

The values for use in the equation is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

In a further embodiment, the slope is calculated by use of the computer software GraphPad Prism 3.0 (GraphPad software, Inc.).

25 In a further embodiment, the value for the slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

is significantly less than the value for the slope calculated with FCCP as test compound in Assay (I).

The present invention also provides for the use of a compound with a Hill slope, n ,
30 calculated as describes in Assay IV herein which is lower than or equal to the Hill slope calculated for FCCP, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating diseases benefiting from an increase in mitochondrial respiration. In a further embodiment, said Hill slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less
35 than 20% of the value of said Hill slope calculated for FCCP.

The present invention also provides the use of a compound for which the value for the glucose utilisation caused by the compound in Assay (I) in concentrations of from CE_{max} to ten times CE_{max} does not fall significantly below the value of E_{max} for the compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a condition benefiting from an increase in mitochondrial respiration in a patient in need thereof. CE_{max} is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

The present invention also provides the use of a chemical compound with an E_{max} in Assay (I), as described in the specification, of less than 75% of the E_{max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazine in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from an increase in mitochondrial respiration in a patient in need thereof.

In a further embodiment, the present invention provides the use of a chemical compound with an E_{max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40% of the E_{max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazine in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from an increase in mitochondrial respiration in a patient in need thereof.

The present invention also provides the use of a chemical compound with an E_{max} in Assay (I), as described in the specification, of less than 75% of the E_{max} of 2,4-dinitrophenol in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from an increase in mitochondrial respiration in a patient in need thereof.

In a further embodiment, the present invention provides the use of a chemical compound with an E_{max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40% of the E_{max} of 2,4-dinitrophenol in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from an increase in mitochondrial respiration in a patient in need thereof.

The E_{max} of the compounds, FCCP and DNP is calculated as described above.

The present invention also provides the use of a chemical compound with a slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

wherein

Y_0 is the degree of stimulation measured as counts per minute (cpm) in Assay (I) in control samples without added test compound,

5 Y_1 is the degree of stimulation measured as cpm in Assay (I) with added test compound in a concentration of either $EC_{50}/2$ or $EC_{50}/3$,

Y_2 is the degree of stimulation measured as cpm in Assay (I) with added test compound in concentration of either $2xEC_{50}$ or $3xEC_{50}$,

X is 2 or 3 depending on which concentration of Y_1 and Y_2 used, and

n is the slope.

10 of a value equal to or less than the value for the slope calculated from the above equation with FCCP as test compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from an increase in mitochondrial respiration in a patient in need thereof. In a further embodiment, said slope for said compound has a value of less than 95%, e.g. less than
15 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said slope calculated for FCCP.

The equation should be understood such that when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/2$, then Y_2 is the degree of stimulation with added test compound in concentration of $2xEC_{50}$, and X is 2, and when Y_1 is the degree
20 of stimulation with added test compound in a concentration of $EC_{50}/3$, then Y_2 is the degree of stimulation with added test compound in a concentration of $3xEC_{50}$, and X is 3.

The values for use in the equation is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

In a further embodiment, the slope is calculated by use of the computer software
25 GraphPad Prism 3.0 (GraphPad software, Inc.).

In a further embodiment, the value for the slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

is significantly less than the value for the slope calculated with FCCP as test compound in Assay (I).

30 The present invention also provides for the use of a compound with a Hill slope, n , calculated as describes in Assay IV herein which is lower than or equal to the Hill slope calculated for FCCP, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from an increase in mitochondrial respiration. In a further embodiment, said Hill slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than
35

70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said Hill slope calculated for FCCP.

The present invention also provides the use of a compound for which the value for the glucose utilisation caused by the compound in Assay (I) in concentrations of from CE_{max} to ten times CE_{max} does not fall significantly below the value of E_{max} for the compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from an increase in mitochondrial respiration in a patient in need thereof. CE_{max} is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

The present invention also provides a method for treating a condition benefiting from an increase in mitochondrial respiration, which method comprises administering a therapeutically effective amount of a compound with an E_{max} in Assay (I), as described in the specification, of less than 75% of the E_{max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazone in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof.

In one embodiment, the present invention provides a method for treating a condition benefiting from an increase in mitochondrial respiration, which method comprises administering a therapeutically effective amount of a compound with an E_{max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40%, such as less than 35%, for instance less than 30%, such as less than 25%, for instance less than 20%, such as less than 15%, for instance less than 10% of the E_{max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazone in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof.

In one embodiment, the present invention provides a method for treating a condition benefiting from an increase in mitochondrial respiration, which method comprises administering a therapeutically effective amount of a compound with an E_{max} in Assay (I), as described in the specification, of less than 75% of the E_{max} of 2,4-dinitrophenol (DNP) in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof.

In one embodiment, the present invention provides a method for treating a condition benefiting from an increase in mitochondrial respiration, which method comprises administering a therapeutically effective amount of a compound with an E_{max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less

than 40%, such as less than 35%, for instance less than 30%, such as less than 25%, for instance less than 20%, such as less than 15%, for instance less than 10% of the E_{\max} of 2,4-dinitrophenol (DNP) in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof.

- 5 The E_{\max} of the compounds, FCCP and DNP is calculated as described below under the heading "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

10 In one embodiment, the present invention provides a method for treating a condition benefiting from an increase in mitochondrial respiration, which method comprises administering a therapeutically effective amount of a compound with a slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

wherein

15 Y_0 is the degree of stimulation measured as counts per minute (cpm) in Assay (I) in control samples without added test compound,

Y_1 is the degree of stimulation measured as cpm in Assay (I) with added test compound in a concentration of either $EC_{50}/2$ or $EC_{50}/3$,

Y_2 is the degree of stimulation measured as cpm in Assay (I) with added test compound in concentration of either $2 \times EC_{50}$ or $3 \times EC_{50}$,

20 X is 2 or 3 depending on which concentration of Y_1 and Y_2 used, and n is the slope.

of a value equal to or less than the value for the slope calculated from the above equation with FCCP as test compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof. In a further embodiment, said slope
25 for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said slope calculated for FCCP.

30 The equation should be understood such that when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/2$, then Y_2 is the degree of stimulation with added test compound in concentration of $2 \times EC_{50}$, and X is 2, and when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/3$, then Y_2 is the degree of stimulation with added test compound in a concentration of $3 \times EC_{50}$, and X is 3.

The values for use in the equation is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

In a further embodiment, the slope is calculated by use of the computer software GraphPad Prism 3.0 (GraphPad software, Inc.).

In a further embodiment, the value for the slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

- 5 is significantly less than the value for the slope calculated with FCCP as test compound in Assay (I).

The present invention also provides for a method for treating a condition benefiting from an increase in mitochondrial respiration, which method comprises administering a therapeutically effective amount of a compound with a Hill slope, n , calculated as describes
10 in Assay IV herein which is lower than or equal to the Hill slope calculated for FCCP, or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof. In a further embodiment, said Hill slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said Hill slope calculated for FCCP.

- 15 In one embodiment, the present invention provides a method for treating a condition benefiting from an increase in mitochondrial respiration, which method comprises administering a therapeutically effective amount of a compound for which the value for the glucose utilisation caused by the compound in Assay (I) in concentrations of from CE_{max} to ten times CE_{max} does not fall significantly below the value of E_{max} for the compound in Assay (I), or a
20 pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof. CE_{max} is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

Such conditions as referred to above as being conditions benefiting from an increase in mitochondrial respiration, may be such conditions as the metabolic syndrome, insulin resistance, dyslipidemia, hypertension, obesity, type 2 diabetes, type 1 diabetes, diabetic
25 late complications including cardiovascular diseases, cardiovascular disorders, disorders of lipid metabolism, neurodegenerative and psychiatric disorders, dysregulation of intraocular pressure including glaucoma, atherosclerosis, hypertension, coronary heart disease, gall-bladder disease, osteoarthritis, and cancer.

- 30 More specifically such conditions include the metabolic syndrome, type 2 diabetes (especially in obese patients), diabetes as a consequence of obesity, insulin resistance, hyperglycemia, prandial hyperglycemia, hyperinsulinemia, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), increased hepatic glucose production, type 1 diabetes, LADA, pediatric diabetes, dyslipidemia (especially in obese patients), diabetic dyslipidemia,
35 hyperlipidemia, hypertriglyceridemia, hyperlipoproteinemia,, micro-/macroalbuminuria, neph-

ropathy, retinopathy, neuropathy, diabetic ulcers, cardiovascular diseases, arteriosclerosis, coronary artery disease, cardiac hypertrophy, myocardial ischemia, heart insufficiency, congestional heart failure, stroke, myocardial infarction, arrhythmia, decreased blood flow, erectile dysfunction (male or female), myopathy, loss of muscle tissue, muscle wasting, muscle catabolism, osteoporosis, decreased linear growth, neurodegenerative and psychiatric disorders, Alzheimers disease, neuronal death, impaired cognitive function, depression, anxiety, eating disorders, appetite regulation, migraine, epilepsy, addiction to chemical substances, disorders of intraocular pressure, bacterial infections, mycobacterial infections. In the present context cancer is intended to include forms such as hematological cancer, such as leukemia, acute myeloide leukemia, chronic myeloide leukemia, chronic lymphatic leukemia, myelodysplasia, multiple myeloma, Hodgkin's disease, or solid tumor forms, such as fibrosarcom, small or non-small cell long carcinoma, gastric, intestinal or colorectal cancer, prostate, endometrial, ovarian or breast cancer, brain, head or neck cancer, cancer in the urinary tract, such as kidney or bladder cancer, malignant melanoma, liver cancer, uterine and pancreatic cancer.

In another embodiment, the invention relates to the use of a chemical uncoupler according to the present invention for maintaining a weight loss.

Uncouplers may also reduce insulin release from β -cells and may thus be useful in providing β -cell rest. Inducing β -cell rest may be useful in connection with β -cell transplantation, and it has also been described that inducing β -cell rest may be useful in preventing diabetes.

The subject may be any mammal suffering from a condition benefiting from increased mitochondrial respiration. Such mammals may include, for instance, horses, cows, sheep, pigs, mice, rats, dogs, cats, primates such as chimpanzees, gorillas, rhesus monkeys, and, most preferably, humans.

Use of the compounds according to the present invention in the treatment of obesity may very likely reduce or eliminate the side effects such as irritation of the skin, glaucoma etc. known from treatment of obesity with DNP and other chemical uncouplers with narrow safety windows.

The present invention also provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 75% of the E_{\max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazine in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for reduction of reactive oxygen species.

In a further embodiment, the present invention provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 70%, such as

less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40%, such as less than 35%, for instance less than 30%, such as less than 25%, for instance less than 20%, such as less than 15%, for instance less than 10% of the E_{\max} of carbonylcyanide *p*-trifluoromethoxy-

5 phenylhydrazone in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for reduction of reactive oxygen species.

The present invention also provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 75% of the E_{\max} of 2,4-dinitrophenol (DNP) in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for re-
10 duction of reactive oxygen species.

In a further embodiment, the present invention provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40%, such as less than 35%, for instance
15 less than 30%, such as less than 25%, for instance less than 20%, such as less than 15%, for instance less than 10% of the E_{\max} of 2,4-dinitrophenol in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for reduction of reactive oxygen species.

The E_{\max} of the compounds, FCCP and DNP is calculated as described below under the heading "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2
20 cells)**".

The present invention also provides the use of a chemical compound with a slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

wherein

25 Y_0 is the degree of stimulation measured as counts per minute (cpm) in Assay (I) in control samples without added test compound,

Y_1 is the degree of stimulation measured as cpm in Assay (I) with added test compound in a concentration of either $EC_{50}/2$ or $EC_{50}/3$,

30 Y_2 is the degree of stimulation measured as cpm in Assay (I) with added test compound in concentration of either $2 \times EC_{50}$ or $3 \times EC_{50}$,

X is 2 or 3 depending on which concentration of Y_1 and Y_2 used, and

n is the slope.

of a value equal to or less than the value for the slope calculated from the above equation with FCCP as test compound in Assay (I), or a pharmaceutically acceptable salt, solvate or
35 prodrug thereof, for reduction of reactive oxygen species. In a further embodiment, said

slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said slope calculated for FCCP.

The equation should be understood such that when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/2$, then Y_2 is the degree of stimulation with added test compound in concentration of $2 \times EC_{50}$, and X is 2, and when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/3$, then Y_2 is the degree of stimulation with added test compound in a concentration of $3 \times EC_{50}$, and X is 3.

The values for use in the equation is calculated as described below under the heading: **"Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)".**

In a further embodiment, the slope is calculated by use of the computer software GraphPad Prism 3.0 (GraphPad software, Inc.).

In a further embodiment, the value for the slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

is significantly less than the value for the slope calculated with FCCP as test compound in Assay (I).

The present invention also provides for the use of a compound with a Hill slope, n , calculated as describes in Assay IV herein which is lower than or equal to the Hill slope calculated for FCCP, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for reduction of reactive oxygen species. In a further embodiment, said Hill slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said Hill slope calculated for FCCP.

The present invention also provides the use of a compound for which the value for the glucose utilisation caused by the compound in Assay (I) in concentrations of from CE_{max} to ten times CE_{max} does not fall significantly below the value of E_{max} for the compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for reduction of reactive oxygen species. CE_{max} is calculated as described below under the heading: **"Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)".**

Reduction of reactive oxygen species as described above may take place *in vitro* or *in vivo*, for instance in an assay or in a subject.

The present invention also provides the use of a chemical compound with an E_{max} in Assay (I), as described in the specification, of less than 75% of the E_{max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazine in Assay (I), or a pharmaceutically acceptable salt, sol-

vate or prodrug thereof, for treating a condition benefiting from a reduction of reactive oxygen species in a patient in need thereof.

In a further embodiment, the present invention provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40%, such as less than 35%, for instance less than 30%, such as less than 25%, for instance less than 20%, such as less than 15%, for instance less than 10% of the E_{\max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazone in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a condition benefiting from a reduction of reactive oxygen species in a patient in need thereof.

The present invention also provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 75% of the E_{\max} of 2,4-dinitrophenol (DNP) in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a condition benefiting from a reduction of reactive oxygen species in a patient in need thereof.

In a further embodiment, the present invention provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40%, such as less than 35%, for instance less than 30%, such as less than 25%, for instance less than 20%, such as less than 15%, for instance less than 10% of the E_{\max} of 2,4-dinitrophenol in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a condition benefiting from a reduction of reactive oxygen species in a patient in need thereof.

The E_{\max} of the compounds, FCCP and DNP is calculated as described above.

The present invention also provides the use of a chemical compound with a slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

wherein

Y_0 is the degree of stimulation measured as counts per minute (cpm) in Assay (I) in control samples without added test compound,
 Y_1 is the degree of stimulation measured as cpm in Assay (I) with added test compound in a concentration of either $EC_{50}/2$ or $EC_{50}/3$,
 Y_2 is the degree of stimulation measured as cpm in Assay (I) with added test compound in concentration of either $2 \times EC_{50}$ or $3 \times EC_{50}$,

X is 2 or 3 depending on which concentration of Y_1 and Y_2 used, and
n is the slope.

of a value equal to or less than the value for the slope calculated from the above equation with FCCP as test compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a condition benefiting from a reduction of reactive oxygen species in a patient in need thereof. In a further embodiment, said slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said slope calculated for FCCP.

The equation should be understood such that when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/2$, then Y_2 is the degree of stimulation with added test compound in concentration of $2 \times EC_{50}$, and X is 2, and when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/3$, then Y_2 is the degree of stimulation with added test compound in a concentration of $3 \times EC_{50}$, and X is 3.

The values for use in the equation is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

In a further embodiment, the slope is calculated by use of the computer software GraphPad Prism 3.0 (GraphPad software, Inc.).

In a further embodiment, the value for the slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

is significantly less than the value for the slope calculated with FCCP as test compound in Assay (I).

The present invention also provides for the use of a compound with a Hill slope, n, calculated as describes in Assay IV herein which is lower than or equal to the Hill slope calculated for FCCP, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a disease benefiting from a reduction in reactive oxygen. In a further embodiment, said Hill slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said Hill slope calculated for FCCP.

The present invention also provides the use of a compound for which the value for the glucose utilisation caused by the compound in Assay (I) in concentrations of from CE_{max} to ten times CE_{max} does not fall significantly below the value of E_{max} for the compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for treating a condition benefiting from a reduction of reactive oxygen species in a patient in need thereof. CE_{max}

is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocyte cell line (HEP-G2 cells)**".

The present invention also provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 75% of the E_{\max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazone in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from a reduction of reactive oxygen species in a patient in need thereof.

In a further embodiment, the present invention provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40%, such as less than 35%, for instance less than 30%, such as less than 25%, for instance less than 20%, such as less than 15%, for instance less than 10% of the E_{\max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazone in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from a reduction of reactive oxygen species in a patient in need thereof.

The present invention also provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 75% of the E_{\max} of 2,4-dinitrophenol (DNP) in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from a reduction of reactive oxygen species in a patient in need thereof.

In a further embodiment, the present invention provides the use of a chemical compound with an E_{\max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40%, such as less than 35%, for instance less than 30%, such as less than 25%, for instance less than 20%, such as less than 15%, for instance less than 10% of the E_{\max} of 2,4-dinitrophenol in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from a reduction of reactive oxygen species in a patient in need thereof.

The E_{\max} of the compounds, FCCP and DNP is calculated as described above.

The present invention also provides the use of a chemical compound with a slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

wherein

Y_0 is the degree of stimulation measured as counts per minute (cpm) in Assay (I) in control samples without added test compound,

Y_1 is the degree of stimulation measured as cpm in Assay (I) with added test compound in a concentration of either $EC_{50}/2$ or $EC_{50}/3$,

5 Y_2 is the degree of stimulation measured as cpm in Assay (I) with added test compound in concentration of either $2xEC_{50}$ or $3xEC_{50}$,

X is 2 or 3 depending on which concentration of Y_1 and Y_2 used, and

n is the slope.

of a value equal to or less than the value for the slope calculated from the above equation with FCCP as test compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from a reduction of reactive oxygen species in a patient in need thereof. In a further embodiment, said slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as
15 less than 20% of the value of said slope calculated for FCCP.

The equation should be understood such that when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/2$, then Y_2 is the degree of stimulation with added test compound in concentration of $2xEC_{50}$, and X is 2, and when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/3$, then Y_2 is the degree of stimulation with added test compound in a concentration of $3xEC_{50}$, and X is 3.
20

The values for use in the equation is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

In a further embodiment, the slope is calculated by use of the computer software GraphPad Prism 3.0 (GraphPad software, Inc.).

25 In a further embodiment, the value for the slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

is significantly less than the value for the slope calculated with FCCP as test compound in Assay (I).

The present invention also provides for the use of a compound with a Hill slope, n , calculated as describes in Assay IV herein which is lower than or equal to the Hill slope calculated for FCCP, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from a reduction in reactive oxygen species. In a further embodiment, said Hill slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%,
30

e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said Hill slope calculated for FCCP.

The present invention also provides the use of a compound for which the value for the glucose utilisation caused by the compound in Assay (I) in concentrations of from CE_{max} to ten times CE_{max} does not fall significantly below the value of E_{max} for the compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the preparation of a pharmaceutical composition for treating a condition benefiting from a reduction of reactive oxygen species in a patient in need thereof. CE_{max} is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

The present invention also provides a method for treating a condition benefiting from a reduction of reactive oxygen species, which method comprises administering a therapeutically effective amount of a compound with an E_{max} in Assay (I), as described in the specification, of less than 75% of the E_{max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazine in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof.

In one embodiment, the present invention provides a method for treating a condition benefiting from a reduction of reactive oxygen species, which method comprises administering a therapeutically effective amount of a compound with an E_{max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less than 40%, such as less than 35%, for instance less than 30%, such as less than 25%, for instance less than 20%, such as less than 15%, for instance less than 10% of the E_{max} of carbonylcyanide *p*-trifluoromethoxy-phenylhydrazine in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof.

In one embodiment, the present invention provides a method for treating a condition benefiting from a reduction of reactive oxygen species, which method comprises administering a therapeutically effective amount of a compound with an E_{max} in Assay (I), as described in the specification, of less than 75% of the E_{max} of 2,4-dinitrophenol (DNP) in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof.

In one embodiment, the present invention provides a method for treating a condition benefiting from a reduction of reactive oxygen species, which method comprises administering a therapeutically effective amount of a compound with an E_{max} in Assay (I), as described in the specification, of less than 70%, such as less than 65%, for instance less than 60%, such as less than 55%, for instance less than 50%, such as less than 45%, for instance less

than 40%, such as less than 35%, for instance less than 30%, such as less than 25%, for instance less than 20%, such as less than 15%, for instance less than 10% of the E_{max} of 2,4-dinitrophenol (DNP) in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof.

- 5 The E_{max} of the compounds, FCCP and DNP is calculated as described below under the heading "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

In one embodiment, the present invention provides a method for treating a condition benefiting from a reduction of reactive oxygen species, which method comprises administering a therapeutically effective amount of a compound with a slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

wherein

- 15 Y_0 is the degree of stimulation measured as counts per minute (cpm) in Assay (I) in control samples without added test compound,
 Y_1 is the degree of stimulation measured as cpm in Assay (I) with added test compound in a concentration of either $EC_{50}/2$ or $EC_{50}/3$,
 Y_2 is the degree of stimulation measured as cpm in Assay (I) with added test compound in concentration of either $2 \times EC_{50}$ or $3 \times EC_{50}$,
 20 X is 2 or 3 depending on which concentration of Y_1 and Y_2 used, and
 n is the slope.

of a value equal to or less than the value for the slope calculated from the above equation with FCCP as test compound in Assay (I), or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof. In a further embodiment, said slope

25 for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said slope calculated for FCCP.

The equation should be understood such that when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/2$, then Y_2 is the degree of stimulation with added test compound in concentration of $2 \times EC_{50}$, and X is 2, and when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/3$, then Y_2 is the degree of stimulation with added test compound in a concentration of $3 \times EC_{50}$, and X is 3.

The values for use in the equation is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

In a further embodiment, the slope is calculated by use of the computer software GraphPad Prism 3.0 (GraphPad software, Inc.).

In a further embodiment, the value for the slope calculated from the equation

$$X^n = (Y_2 - Y_0) / (Y_1 - Y_0)$$

- 5 is significantly less than the value for the slope calculated with FCCP as test compound in Assay (I).

The present invention also provides for the a method of treating a condition benefiting from a reduction in reactive oxygen species, which method comprises administering a therapeutically effective amount of a compound with a Hill slope, n , calculated as describes
10 in Assay IV herein which is lower than or equal to the Hill slope calculated for FCCP, or a pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof. In a further embodiment, said Hill slope for said compound has a value of less than 95%, e.g. less than 90%, e.g. less than 80%, e.g. less than 70%, e.g. less than 50%, e.g. less than 40%, such as less than 20% of the value of said Hill slope calculated for FCCP.

- 15 In one embodiment, the present invention provides a method for treating a condition benefiting from a reduction of reactive oxygen species, which method comprises administering a therapeutically effective amount of a compound for which the value for the glucose utilisation caused by the compound in Assay (I) in concentrations of from CE_{max} to ten times CE_{max} does not fall significantly below the value of E_{max} for the compound in Assay (I), or a
20 pharmaceutically acceptable salt, solvate or prodrug thereof, to a patient in need thereof. CE_{max} is calculated as described below under the heading: "**Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)**".

- Such conditions as referred to above as being conditions benefiting from a reduction of reactive oxygen species may be such conditions as the aging process, damage of heart
25 tissue, endothelia cells as well as damage of neuronal tissue.


The subject may be any mammal suffering from a condition benefiting from a reduction of reactive oxygen species. Such mammals may include, for instance, horses, cows, sheep, pigs, mice, dogs, cats, primates such as chimpanzees, gorillas, rhesus monkeys, and, most preferably, humans.

- 30 It is well-known that many compounds used to combat insects and parasites, i.e. insecticides and parasiticides, are chemical uncouplers. It is speculated that some of the adverse effects sometimes observed on animals or humans treated with or subjects exposed to such compounds may be caused by the fact that these compounds are not safe chemical uncouplers. It is thus believed that uncouplers according to the present invention could be

28


used as insecticides or parasiticides with a lower risk to subjects treated with or exposed to the compounds.

In one embodiment, the invention the compound to be used is of the general formula I



(I)

wherein



is an aryl, or heteroaryl,

R^1 is halogen, $-\text{CHO}$, $-\text{CO}_2R^{32}$, $-\text{COR}^{32}$, $-\text{SO}_3\text{H}$, $-\text{CCl}_3$, $-\text{CF}_3$, $-\text{NO}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{CH}=\text{CH}-R^{33}$,
 10 $-\text{C}(R^{33})(R^{34})$, $-\text{SOR}^{32}$, $-\text{SO}_2R^{32}$ or aryl substituted with from one to five substituents selected from halogen, $-\text{CHO}$, $-\text{CO}_2R^{32}$, $-\text{COR}^{32}$, $-\text{SO}_3\text{H}$, $-\text{CCl}_3$, $-\text{CF}_3$, $-\text{NO}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{CH}=\text{CH}-R^{33}$, $-\text{CH}(R^{33})(R^{34})$, $-\text{SOR}^{32}$, $-\text{SO}_2R^{32}$, wherein

R^{32} is hydrogen, alkyl, aryl, or heteroaryl; and

R^{33} and R^{34} independently of each other are halogen, $-\text{CHO}$, $-\text{CO}_2R^{35}$, $-\text{COR}^{35}$,
 15 $-\text{SO}_3\text{H}$, $-\text{CCl}_3$, $-\text{CF}_3$, $-\text{NO}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{SOR}^{35}$, $-\text{SO}_2R^{35}$, wherein

R^{35} is hydrogen or alkyl;

and is attached on a carbon atom adjacent to the carbon atom to which the hydroxy group is attached;


R^2 is $\text{C}(\text{X})_3$, NO_2 , alkyl, nitro, halogen, alkyl-O-, alkyl-C(O)-, alkyl-C(O)-O-, or aryl, wherein

20 X is halogen; and

R^3 and R^4 independently of each other are hydrogen, alkyl, nitro, halogen, alkyl-O-, alkyl-C(O)-, alkyl-C(O)-O-, or aryl;

or

R^2 and R^3 together forms one of the diradicals



25


wherein

R^{36} and R^{37} , independently of each other, are hydrogen, halogen, $C(X)_3$, nitro, cyano, alkyl, alkyl-O-, alkyl-C(O)-, or aryl, wherein




X is halogen;

- 5 and where the two connecting atoms are connected to adjacent carbon atoms; and R^4 is hydrogen, halogen, $C(X)_3$, nitro, cyano, alkyl, alkyl-O-, alkyl-C(O)-, or aryl, or a pharmaceutically acceptable salt, solvate or prodrug thereof.


In one embodiment,




is an aryl, and in particular an aryl selected from




, or




Special mentioning is made of embodiments, wherein



is




In another embodiment,



is a heteroaryl, and in particular a heteroaryl selected from


30



In any of the above mentioned embodiments relating compounds of formula I, R^1 may represent halogen, -CHO, -CO₂R³², -COR³², -SO₃H, -CCl₃, -CF₃, -NO, -NO₂, -CN, -CH=CH-R³³, -CH(R³³)(R³⁴), -SOR³², -SO₂R³², wherein R³², R³³ and R³⁴ are as defined above. In particular, R^1 may represent nitro. In particular, R³² may represent hydrogen.

In any of the above mentioned embodiments relating to compounds of formula I, R³³ and R³⁴ may independently of each other represent halogen, -CHO, -CO₂H, -COH, -SO₃H, -CCl₃, -CF₃, -NO, -NO₂, -CN, -SOH, -SO₂H.

In any of the above embodiments relating to compounds of formula I, R² may represent C(X)₃, alkyl, nitro, halogen, alkyl-O-, or alkyl-C(O)-, wherein X is halogen. In particular, R² may represent alkyl, such as C₁₋₆-alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and hexyl, and in particular methyl. R² may also represent alkyl-O-, such as C₁₋₆-alkyl-O-, e.g. wherein the alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and hexyl, and in particular methyl. R² may also represent alkyl-C(O)-, such as C₁₋₆-alkyl-C(O)-, e.g. wherein the alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and hexyl, and in particular methyl. R² may also represent alkyl-C(O)-O-, such as C₁₋₆-alkyl-C(O)-O-, e.g. wherein the alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and hexyl, and in particular methyl. R² may also represent C(X)₃, wherein X is halogen, such as chloro or fluoro. R² and R³ may also together form the diradical




wherein R^{36} and R^{37} , independently of each other, represent hydrogen, halogen, $C(X)_3$, nitro, cyano, alkyl, alkyl-O-, alkyl-C(O)-, or aryl, wherein X represents halogen. In particular R^{36} and/or R^{37} may represent hydrogen.

In any of the above embodiment relating to compounds of formula I, except for those
5 embodiments wherein R^2 together with R^3 forms a diradical, R^3 may represent hydrogen.

In any of the above embodiment relating to compounds of formula I R^4 may represent hydrogen.


In particular, compounds of formula I may be selected from the list comprising
4-methoxy-2-nitrophenol,
10 4-hydroxy-3-nitroacetophenone, or
7-hydroxy-4-methyl-8-nitro-chromen-2-one.

In one embodiment of the present invention, the compound to be used is of the general formula II




15

wherein A^1 is



, wherein



is an aryl, or heteroaryl;


20 R^{38} is halogen, -CHO, $-CO_2R^{42}$, $-COR^{42}$, $-SO_3H$, $-CCl_3$, $-CF_3$, -NO, $-NO_2$, -CN, $-SOR^{42}$, or $-SO_2R^{42}$, wherein R^{42} is hydrogen or alkyl; and wherein R^{38} is attached to a carbon atom adjacent to the carbon atom to which the hydroxy group is attached;

R^{39} , R^{40} , and R^{41} independently of each other represent hydrogen, alkyl, nitro, cyano, halogen, alkyl-O-, alkyl-C(O)-, alkyl-C(O)-O-, or aryl;


25 R^5 is hydrogen or alkyl; and
n is an integer of from 0 to 10

or a pharmaceutically acceptable salt, solvate or prodrug thereof.


In one embodiment of the invention relating to formula I




is an aryl, such as




5 and in particular



In another embodiment of the invention relating compounds of formula II



represent a heteroaryl, such as



10


In any of the embodiment of the present invention relating to compounds of formula II, R^{38} may represent halogen, -CHO, -CO₂H, -COH, -SO₃H, -CCl₃, -CF₃, -NO, -NO₂, -CN, -SOH, or -SO₂H, and in particular nitro.

In any of the above embodiments of the present invention relating to compounds of formula II, at least one, or at least two, or all of R^{39} , R^{40} , and R^{41} represent hydrogen.

In any of the above embodiments of the present invention relating to compounds of formula II, n may represent an integer of from 0 to 6, such as an integer of from 0 to 2, such as 1 or 2, and in particular 1.

In particular, compounds of formula II may be selected from the list consisting of 4,4-bis-(4-hydroxy-3-nitrophenyl)-valeric acid.

In one embodiment of the present invention the compound to be used is of the general formula III




(III)

wherein

R^6 is halogen, $-\text{CHO}$, $-\text{CO}_2R^{43}$, $-\text{COR}^{43}$, $-\text{SO}_3\text{H}$, $-\text{CCl}_3$, $-\text{CF}_3$, $-\text{NO}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{CH}=\text{CH}-R^{44}$, $-\text{C}(R^{44})(R^{45})$, $-\text{SOR}^{43}$, $-\text{SO}_2R^{43}$ or aryl substituted with from one to five substituents selected from halogen, $-\text{CHO}$, $-\text{CO}_2R^{43}$, $-\text{COR}^{43}$, $-\text{SO}_3\text{H}$, $-\text{CCl}_3$, $-\text{CF}_3$, $-\text{NO}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{CH}=\text{CH}-R^{44}$, $-\text{CH}(R^{44})(R^{45})$, $-\text{SOR}^{43}$, $-\text{SO}_2R^{43}$, wherein R^{43} represents hydrogen or alkyl; and R^{44} and R^{45} independently of each other represent halogen, $-\text{CHO}$, $-\text{CO}_2R^{46}$, $-\text{COR}^{46}$, $-\text{SO}_3\text{H}$, $-\text{CCl}_3$, $-\text{CF}_3$, $-\text{NO}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{SOR}^{46}$, $-\text{SO}_2R^{46}$, wherein R^{46} is hydrogen, alkyl, or aryl; R^7 represents alkyl, nitro, halogen, alkyl-O-, alkyl-C(O)-, or alkyl-C(O)-O-; and R^8 and R^9 independently of each other represent hydrogen, alkyl, nitro, halogen, alkyl-O-, alkyl-C(O)-, alkyl-C(O)-O-, or aryl;

or

R^7 and R^8 together forms the diradical



wherein R^{47} and R^{48} , independently of each other, are hydrogen, alkyl, nitro, halogen, alkyl-O-, alkyl-C(O)-, or alkyl-C(O)-O-;


wherein the two valence atoms are connected to adjacent carbon atoms;

and R^9 is hydrogen, alkyl, nitro, halogen, alkyl-O-, or alkyl-C(O)-;
and a pharmaceutically acceptable salt, solvate or prodrug thereof.

In one embodiment of the present invention relating to compounds of formula III, R^6 represents halogen, -CHO, -CO₂R⁴³, -COR⁴³, -SO₃H, -CCl₃, -CF₃, -NO, -NO₂, -CN,
5 -CH=CH-R⁴⁴, -CH(R⁴⁴)(R⁴⁵), -SOR⁴³, -SO₂R⁴³. In particular, R⁴³ may represent hydrogen, or R⁴⁴ and R⁴⁵ independently of each other may represent halogen, -CHO, -CO₂H, -COH, -SO₃H, -CCl₃, -CF₃, -NO, -NO₂, -CN, -SOH, -SO₂H.

In any of the above mentioned embodiment relating to compounds of formula III, R^6 may represent cyano or nitro, and in particular is nitro.

10 In any of the above mentioned embodiment relating to compounds of formula III, R^7 may represent alkyl, nitro, halogen, alkyl-O-, or alkyl-C(O)-. In particular, R^7 may represent alkyl, such as C₁₋₆-alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, or 1,1-dimethylpropyl, and in particular methyl. In particular, R^7 may represent alkyl-O-, such as C₁₋₆-alkyl-O-, e.g. wherein alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, tert-
15 butyl, pentyl and hexyl, and in particular methyl. In particular, R^7 may represent alkyl-C(O)-, such as C₁₋₆-alkyl-C(O)-, e.g. wherein alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and hexyl, and in particular methyl. In particular, R^7 may represent alkyl-C(O)-O-, such as C₁₋₆-alkyl-C(O)-O-, e.g. wherein alkyl is selected from methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and hexyl, and in particular methyl. R^7 and R^8 may
20 also together form the diradical




wherein R^{47} and R^{48} , independently of each other, are hydrogen, alkyl, nitro, halogen, alkyl-O-, alkyl-C(O)-, or alkyl-C(O)-O-. In particular, R^{47} and/or R^{48} may represent hydrogen.

In one embodiment relating to compounds of formula III, R^8 may represent
25 hydrogen.

In any of the above mentioned embodiments relating to compounds of formula III, R^9 may represent hydrogen.

35

In one embodiment of the invention, the compound to be used is of the formula IV



(IV)

wherein

5 R^{10} , R^{11} and R^{12} independently of each other are hydrogen, trifluoromethyl, nitro, cyano, alkyl-S-, SO_y , R^{49} -O-, $N(R^{50})(R^{51})$ -, alkyl, halogen, or aryl-S-, wherein y is an integer of 1 or 2;

R^{49} , R^{50} and R^{51} independently of each other are hydrogen or alkyl;

wherein at least one of R^{10} , R^{11} and R^{12} is different from hydrogen;

10 and

R^{13} , R^{14} , R^{15} , R^{16} and R^{17} independently of each other are hydrogen, halogen, hydroxy, halogen, cyano, or alkyl, aryl, aryl-S-, or heteroaryl, optionally substituted with halogen;

or

15 R^{13} and R^{14} together form a conjugated alkenylene, which together with the benzene ring forms a fused aromatic ring system, which may optionally be substituted with one or more substituents selected from the group consisting of hydroxy, methyl, halogen, CF_3 , alkyl-O-, nitro, and cyano; and

20 R^{15} , R^{16} and R^{17} , independently of each other, are hydrogen, halogen, hydroxy, halogen, or alkyl optionally substituted with halogen

or

25 R^{14} and R^{15} together form a conjugated alkenylene, which together with the benzene ring forms a fused aromatic ring system, which may optionally be substituted with one or more substituents selected from the group consisting of hydroxy, methyl, halogen, CF_3 , alkyl-O-, nitro, and cyano; and

36


R^{13} , R^{16} and R^{17} independently of each other are hydrogen, halogen, hydroxy, halogen, or alkyl, aryl or heteroaryl, optionally substituted with halogen;

and

5 R^{18} is hydrogen;

and a pharmaceutically acceptable salt, solvate or prodrug thereof. In particular, at least two of R^{10} , R^{11} and R^{12} is different from hydrogen. In particular, R^{10} represents nitro.


In any of the above mentioned embodiments of the invention relating to compounds of formula IV, R^{10} may represent nitro. In particular, the compound may be of formula IVa



10

(IVa)

wherein R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} are as defined above. R^{10} may also represent cyano, and in particular, the compound may be of formula IVb




15

(IVb)

wherein R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} are as defined above.

In any of the above mentioned claims relating to compounds of formula IV, R^{11} may represent halogen, e.g. chloro, and in particular, the compound may be of formula IVc




20

(IVc)

37

wherein R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} are as defined above.

In another embodiment, the compound of formula IV is of formula IVd




(IVd)

- 5 wherein R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} are as defined above with the proviso that R^{10} and R^{11} are different from hydrogen. In particular, R^{10} may represent nitro or cyano. In particular, R^{11} may represent halogen, e.g. chloro. In particular, R^{12} may represent hydrogen.


- In any of the above embodiment relating to compounds of formula IV, at least one, e.g. at least two of R^{13} , R^{14} , R^{15} , R^{16} and R^{17} may be different from hydrogen. In particular, at least one of R^{13} , R^{14} , R^{15} , R^{16} and R^{17} is hydroxy. In particular, at least one of R^{13} , R^{14} , R^{15} , R^{16} and R^{17} is alkyl, such as C_{1-6} -alkyl, such as neopentyl, adamantyl, tert-butyl, 1-methylcyclopentyl, cyclopropyl, cyclobutyl, isopropyl, or 1,1-dimethylpropyl, and in particular methyl. In particular, at least one of R^{13} , R^{14} , R^{15} , R^{16} and R^{17} is alkyl substituted with halogen, such as at least one, e.g. at least two of R^{13} , R^{14} , R^{15} , R^{16} and R^{17} is trifluoromethyl. In particular, R^{17} is alkyl, such as C_{1-6} -alkyl, e.g. neopentyl, adamantyl, tert-butyl, isopropyl, or 1,1-dimethylpropyl, and in particular isopropyl, is tert-butyl or methyl. In particular, R^{13} is hydroxy. In particular, R^{14} is alkyl, such as C_{1-6} -alkyl, e.g. neopentyl, adamantyl, tert-butyl, isopropyl, or 1,1-dimethylpropyl, and in particular isopropyl, tert-butyl or methyl. In particular, R^{14} is aryl-S-, such as phenyl-S-. In particular, R^{14} is trifluoromethyl. In particular, R^{14} and R^{16} are trifluoromethyl.

- In another embodiment relating to the compound of formula IV, at least two of R^{13} , R^{14} , R^{15} , R^{16} and R^{17} are different from hydrogen. In particular, R^{13} and R^{14} together form a conjugated C_{3-5} -alkenylene, which together with the benzene ring forms a fused aromatic ring system, which may optionally be substituted with one or more substituents selected from the group consisting of hydroxy, methyl, halogen, CF_3 , alkyl-O-, nitro, and cyano. In particular, R^{13} and R^{14} together form



, which may optionally be substituted with one or more substituents selected from the group consisting of hydroxy, methyl, halogen, CF_3 , alkyl-O-, nitro, and cyano. In particu-

lar, R^{15} , R^{16} , and R^{17} all are hydrogen. In particular, at least one, e.g. at least two of R^{15} , R^{16} , and R^{17} is different from hydrogen, such as at least one of R^{15} , R^{16} , and R^{17} is hydroxy. In particular, at least one of R^{15} , R^{16} , and R^{17} is alkyl, e.g. C_{1-6} -alkyl, e.g. neopentyl, adamantyl, tert-butyl, isopropyl, or 1,1-dimethylpropyl, aryl or heteroaryl, optionally substituted with halogen. In particular, at least one, such as at least two of R^{15} , R^{16} , and R^{17} is C_{1-6} -alkyl substituted with halogen, such as trifluoromethyl. In particular, at least one of R^{15} , R^{16} , and R^{17} is methyl. In particular, R^{17} is alkyl, such as C_{1-6} -alkyl, e.g. neopentyl, adamantyl, tert-butyl, isopropyl, or 1,1-dimethylpropyl, and in particular isopropyl, tert-butyl or methyl. In particular, R^{14} and R^{15} together form a conjugated C_{3-5} -alkenylene, which together with the benzene ring forms a fused aromatic ring system, which may optionally be substituted with one or more substituents selected from the group consisting of hydroxy, methyl, halogen, CF_3 , alkyl-O-, nitro, and cyano, examples of which includes compounds wherein R^{14} and R^{15} together form



, which may optionally be substituted with one or more substituents selected from the group consisting of hydroxy, methyl, halogen, CF_3 , alkyl-O-, nitro, and cyano. In particular, R^{13} , R^{16} , and R^{17} all are hydrogen. In particular, at least one, such as at least two of R^{13} , R^{16} , and R^{17} is different from hydrogen. In particular, at least one of R^{13} , R^{16} , and R^{17} is hydroxyl or at least one of R^{13} , R^{16} , and R^{17} is alkyl, e.g. C_{1-6} -alkyl, aryl or heteroaryl, optionally substituted with halogen. Specific examples of said alkyl include is neopentyl, adamantyl, tert-butyl, isopropyl, or 1,1-dimethylpropyl, or C_{1-6} -alkyl substituted with halogen, such as trifluoromethyl. In particular, at least two of R^{13} , R^{16} , and R^{17} is trifluoromethyl. In particular, at least one of R^{13} , R^{16} , and R^{17} is methyl. In particular, R^{17} is alkyl, such as C_{1-6} -alkyl, e.g. neopentyl, adamantyl, tert-butyl, isopropyl, or 1,1-dimethylpropyl, and in particular isopropyl, tert-butyl or methyl. In particular, R^{13} is hydroxy.


In any of the above embodiments of the invention relating to compounds of formula IV, R^{13} , R^{14} , R^{15} , R^{16} and R^{17} may all represent hydrogen.

In any of the above embodiments of the invention relating to compounds of formula IV, R^{18} may represent hydrogen, or R^{18} may represent alkyl, such as C_{1-6} -alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl and hexyl, and in particular methyl.

Specific examples of compounds according to formula IV include
 tert-butyl-5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-methylbenzamide,
 N-1-[4-cyano-3-(trifluoromethyl)phenyl]-3,5-di(trifluoromethyl)benzamide,
 N-(4-cyanophenyl)benzamide,
 2'-chloro-1-hydroxy-4'-nitro-2-naphthanilide,

N-(2-chloro-4-bromophenyl)-5-bromosalicylanilide,
 N-(2-chloro-4-nitrophenyl)-3-tert-butyl-6-methylsalicylanilide,
 3,6-dinitrocarbazole, or
 N-(3-cyano-4-phenylsulfanyl-phenyl)-3-trifluoromethyl-benzamide.

5 In one embodiment of the invention, the compound to be used is of formula V



wherein R^{19} and R^{20} independently of each other are alkyl;

and

10 R^{21} , R^{22} and R^{23} independently of each other are selected from alkyl, cycloalkyl, or aryl and a pharmaceutically acceptable salt, solvate or prodrug thereof.

In one embodiment relating to compounds of formula V, R^{19} and R^{20} independently of each other are C_{1-6} -alkyl, such as neopentyl, adamantyl, tert-butyl, isopropyl, or 1,1-dimethylpropyl, and in particular isopropyl or tert-butyl.


15 In any of the above embodiment of the invention relating to compounds of formula V, R^{21} , R^{22} and R^{23} may independently of each other represent C_{1-12} -alkyl, C_{3-8} -cycloalkyl, or aryl, and in particular aryl. In particular, at least one, e.g. all of R^{21} , R^{22} and R^{23} is phenyl. R^{21} , R^{22} and R^{23} may also independently of each other represent cycloalkyl, e.g. C_{3-8} -cycloalkyl. In particular, at least one, e.g. all of R^{21} , R^{22} and R^{23} represent cyclohexyl. R^{21} , R^{22} and R^{23} may also independently of each other represent alkyl, such as C_{1-12} -alkyl, e.g. C_{1-8} -alkyl, e.g. C_{1-6} -alkyl. In particular, at least one, e.g. all of R^{21} , R^{22} and R^{23} represent heptyl or octyl.

Specific examples of compounds according to formula V include

(3,5-di-tert-butyl-4-hydroxybenzyl)triphenylphosphonium bromide,
 (3,5-di-tert-butyl-4-hydroxybenzyl)tricyclohexylphosphonium bromide,
 25 (3,5-di-tert-butyl-4-hydroxybenzyl)tributylphosphonium bromide, or
 (3,5-di-tert-butyl-4-hydroxybenzyl)trioctylphosphonium bromide.

40

In one embodiment of the invention, the compound to be used is a compound according to formula VI



(VI)

wherein

R^{24} and R^{25} independently of each other are alkyl or cycloalkyl;
and

X is $=C(R^{52})-$; wherein

R^{52} is hydrogen, cyano, nitro, alkyl- $S(O)_2-$, tetrazole, alkyl-S-, alkyl-C(O)-, or alkyl-O-C(O)-, halogen, haloalkyl, $(R^{53})_2-N-C(O)-$, $-P(O)(O-R^{53})_2$, aryl, heteroaryl, wherein said aryl and heteroaryl are optionally substituted with one or more substituents selected from nitro, cyano, halogen, haloalkyl, -C(O)- R^{53} , -C(O)-O- R^{53} , -C(O)-N- $(R^{53})_2$, - $S(O)_2$ -O- R^{53} , -S(O)- R^{53} , - $S(O)_2$ - R^{53} , - $S(O)_2$ -N- $(R^{53})_2$, or -O- R^{53} , wherein

R^{53} is hydrogen, or alkyl or phenyl optionally substituted with halogen; and


R^{26} is cyano, nitro, R^{54} - $S(O)_2-$, tetrazole, alkyl-C(O)-, or alkyl-O-C(O)-, haloalkyl, -S(O)-alkyl, - $S(O)_2$ -alkyl, - $S(O)_2$ -N- $(R^{54})_2$, -C(O)-N- $(R^{54})_2$, wherein

R^{54} is hydrogen, or alkyl or phenyl optionally substituted with halogen;

or

X is =N-, and

R^{26} is cyano, nitro, R^{54} - $S(O)_2-$, alkyl-C(O)-, alkyl-O-C(O)-, or



wherein

R^{54} is hydrogen, or alkyl or phenyl optionally substituted with halogen; and

R^{55} and R^{56} independently of each other are cyano, nitro, R^{57} -S(O)₂-, alkyl-C(O)-, or alkyl-O-C(O)-, wherein

R^{57} is hydrogen, or alkyl or phenyl optionally substituted with halogen;

5 and a pharmaceutically acceptable salt, solvate or prodrug thereof.

In one embodiment relating to compounds of formula VI, R^{24} and R^{25} may independently of each other represent alkyl, such as C₁₋₆-alkyl, e.g. neopentyl, adamantyl, tert-butyl, isopropyl, or 1,1-dimethylpropyl, and in particular tert-butyl, isopropyl or cycloalkyl. R^{24} and R^{25} may also independently of each other represent C₃₋₈-cycloalkyl.

10 Particular examples of compounds of formula VI includes


2-cyano-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-acrylic acid ethyl ester,

2-(3,5-di-tert-butyl-4-hydroxy-benzylidene)-malonic acid diethyl ester,

2-amino-S-[(3,5-di-tert-butyl-4-hydroxybenzylidene)-amino]-but-2-enedinitrile, or

2-(3,5-di-tert-butyl-4-hydroxy-benzylidene)-indan-1,3-dione.

15 In another embodiment of the invention, the compound to be used is of formula VII



(VII)

wherein

R^{27} is hydrogen or alkyl-O-CH₂-;

20 R^{28} and R^{29} independently of each other are hydrogen, halogen, dicyanovinyl, cyano, nitro, dinitrovinyl, alkyl optionally substituted with halogen, or aryl optionally substituted with one or more substituents selected from the group consisting of halogen, dicyanovinyl, cyano, nitro, and dinitrovinyl,

or

25 R^{28} and R^{29} together forms a benzene ring optionally substituted with one or more substituents selected from the group consisting of halogen, C₁₋₆-alkyl, dicyanovinyl, cyano, nitro, and dinitrovinyl;

and

R^{30} is halogen, dicyanovinyl, cyano, nitro, dinitrovinyl, alkyl optionally substituted with halogen, or aryl optionally substituted with one or more substituents selected from the group consisting of halogen, dicyanovinyl, cyano, nitro, and dinitrovinyl; and R^{31} is hydrogen, halogen, dicyanovinyl, cyano, nitro, dinitrovinyl, alkyl optionally substituted with halogen, or aryl optionally substituted with one or more substituents selected from the group consisting of halogen, dicyanovinyl, cyano, nitro, and dinitrovinyl;
or
 R^{30} and R^{31} together forms a benzene ring optionally substituted with one or more substituents selected from the group consisting of halogen, C_{1-6} -alkyl, dicyanovinyl, cyano, nitro, and dinitrovinyl,
and a pharmaceutically acceptable salt, solvate or prodrug thereof.

In one embodiment relating to compounds of formula VII, R^{27} is hydrogen or C_{1-6} -alkyl-O-CH₂-, e.g. H₃C-CH₂-O-CH₂-. In particular R^{27} may represent hydrogen. In particular, R^{27} may represent C_{1-6} -alkyl-O-CH₂-.

In any of the above embodiments relating to compounds of formula VII, R^{28} and R^{29} independently of each other may represent hydrogen, halogen, dicyanovinyl, cyano, nitro, dinitrovinyl, alkyl optionally substituted with halogen, or aryl optionally substituted with one or more substituents selected from the group consisting of halogen, dicyanovinyl, cyano, nitro, and dinitrovinyl. In particular, R^{28} and R^{29} independently of each other may represent halogen, cyano, C_{1-6} -alkyl optionally substituted with halogen, or aryl optionally substituted with one or more substituents selected from the group consisting of halogen, dicyanovinyl, cyano, nitro, and dinitrovinyl. In particular, at least one of R^{28} and R^{29} is C_{1-6} -alkyl substituted with halogen, such as trifluoromethyl. In particular, at least one of R^{28} and R^{29} is C_{1-6} -alkyl, such as ethyl or methyl. In particular, at least one of R^{28} and R^{29} is halogen or cyano. In particular, at least one of R^{28} and R^{29} is aryl, e.g. phenyl optionally substituted with one or more substituents selected from the group consisting of halogen, dicyanovinyl, cyano, nitro, and dinitrovinyl. R^{28} and R^{29} may also together form a benzene ring optionally substituted with one or more substituents selected from the group consisting of halogen, C_{1-6} -alkyl, dicyanovinyl, cyano, nitro, and dinitrovinyl, and in particular, said benzene ring is unsubstituted or substituted. R^{30} and R^{31} may also together form a benzene ring optionally substituted with one or more substituents selected from the group consisting of halogen, C_{1-6} -alkyl, dicyanovinyl, cyano, nitro, and dinitrovinyl, and in particular, said benzene ring may be substituted or unsubstituted. R^{30} may also represent alkyl optionally substituted with halogen, or aryl optionally substituted with one or more substituents selected from the group consisting of halogen, di-

cyanovinyl, cyano, nitro, and dinitrovinyl, and in particular the substituent is halogen. In particular, R^{30} is alkyl, e.g. C_{1-6} -alkyl optionally substituted with halogen, such as methyl or trifluoromethyl. R^{30} may also represent aryl, e.g. phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, dicyanovinyl, cyano, nitro, and dinitrovinyl. In particular, R^{31} is hydrogen, dicyanovinyl, cyano, dinitrovinyl, or alkyl, e.g. C_{1-6} -alkyl, optionally substituted with halogen. Particular examples of R^{31} include hydrogen, dicyanovinyl, cyano, dinitrovinyl, or methyl.

Specific examples of compounds according to formula VII include

2-[[2-(4-chlorophenyl)-1H-indol-3-yl]methylene]malononitrile,

2-(4-chlorophenyl)-indole,

2,3-dimethyl-5-cyano-7-ethylindole, or

4-bromo-2-(4-chlorophenyl)-1-ethoxymethyl-5-trifluoromethyl-1H-pyrrole-3-carbonitril.

In one embodiment, the invention provides compounds according to any of formula I-VII.

In a use or a method according to the present invention, the compound may also be administered in combination with one or more further active substances in any suitable ratios. Such further active agents may be selected from antidiabetic agents, antihyperlipidemic agents, antiobesity agents, antihypertensive agents and agents for the treatment of complications resulting from or associated with diabetes.

Suitable antidiabetic agents include insulin, GLP-1 (glucagon like peptide-1) derivatives such as those disclosed in WO 98/08871 (Novo Nordisk A/S), which is incorporated herein by reference, as well as orally active hypoglycemic agents.

Suitable orally active hypoglycemic agents preferably include imidazolines, sulfonyleureas, biguanides, meglitinides, oxadiazolidinediones, thiazolidinediones, insulin sensitizers, α -glucosidase inhibitors, agents acting on the ATP-dependent potassium channel of the pancreatic β -cells eg potassium channel openers such as those disclosed in WO 97/26265, WO 99/03861 and WO 00/37474 (Novo Nordisk A/S) which are incorporated herein by reference, potassium channel openers, such as ormitiglinide, potassium channel blockers such as nateglinide or BTS-67582, glucagon antagonists such as those disclosed in WO 99/01423 and WO 00/39088 (Novo Nordisk A/S and Agouron Pharmaceuticals, Inc.), all of which are incorporated herein by reference, GLP-1 agonists such as those disclosed in WO 00/42026 (Novo Nordisk A/S and Agouron Pharmaceuticals, Inc.), which are incorporated herein by reference, DPP-IV (dipeptidyl peptidase-IV) inhibitors, PTPase (protein tyrosine phosphatase) inhibitors, glucokinase activators, such as those described in WO 02/08209 to Hoffmann La Roche, inhibitors of hepatic enzymes involved in stimulation of gluconeogene-

sis and/or glycogenolysis, glucose uptake modulators, GSK-3 (glycogen synthase kinase-3) inhibitors, compounds modifying the lipid metabolism such as antihyperlipidemic agents and antilipidemic agents, compounds lowering food intake, and PPAR (peroxisome proliferator-activated receptor) and RXR (retinoid X receptor) agonists such as ALRT-268, LG-1268 or
5 LG-1069.

In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with insulin or insulin analogues.

In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with a sulphonylurea eg tolbutamide, chlor-
10 propamide, tolazamide, glibenclamide, glipizide, glimepiride, glicazide or glyburide.

In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with a biguanide eg metformin.

In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with a meglitinide eg repaglinide or sena-
15 glinide/nateglinide.

In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with a thiazolidinedione insulin sensitizer eg troglitazone, ciglitazone, pioglitazone, rosiglitazone, isaglitazone, darglitazone, englitazone, CS-011/CI-1037 or T 174 or the compounds disclosed in WO 97/41097 (DRF-2344), WO
20 97/41119, WO 97/41120, WO 00/41121 and WO 98/45292 (Dr. Reddy's Research Foundation), which are incorporated herein by reference.

In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with an insulin sensitizer eg such as GI 262570, YM-440, MCC-555, JTT-501, AR-H039242, KRP-297, GW-409544, CRE-16336,
25 AR-H049020, LY510929, MBX-102, CLX-0940, GW-501516 or the compounds disclosed in WO 99/19313 (NN622/DRF-2725), WO 00/50414, WO 00/63191, WO 00/63192, WO 00/63193 (Dr. Reddy's Research Foundation) and WO 00/23425, WO 00/23415, WO 00/23451, WO 00/23445, WO 00/23417, WO 00/23416, WO 00/63153, WO 00/63196, WO 00/63209, WO 00/63190 and WO 00/63189 (Novo Nordisk A/S), which are incorporated
30 herein by reference.

In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with an α -glucosidase inhibitor eg voglibose, emiglitate, miglitol or acarbose.

In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with a glycogen phosphorylase inhibitor eg the compounds described in WO 97/09040 (Novo Nordisk A/S).

5 In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with a glucokinase activator.

In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with an agent acting on the ATP-dependent potassium channel of the pancreatic β -cells eg tolbutamide, glibenclamide, glipizide, glipizide, BTS-67582 or repaglinide.

10 In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with nateglinide.

In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with an antihyperlipidemic agent or a antilipidemic agent eg cholestyramine, colestipol, clofibrate, gemfibrozil, lovastatin, pravastatin, simvastatin, probucol or dextrothyroxine.

15 In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with more than one of the above-mentioned compounds eg in combination with metformin and a sulphonylurea such as glyburide; a sulphonylurea and acarbose; nateglinide and metformin; acarbose and metformin; a sulphonylurea, metformin and troglitazone; insulin and a sulphonylurea; insulin and metformin; insulin, metformin and a sulphonylurea; insulin and troglitazone; insulin and lovastatin; etc.

In one embodiment of the uses and methods of the present invention, the compound involved may be administered in combination with one or more antiobesity agents or appetite regulating agents.

25 Such agents may be selected from the group consisting of CART (cocaine amphetamine regulated transcript) agonists, NPY (neuropeptide Y) antagonists, MC3 (melanocortin 3) agonists, MC4 (melanocortin 4) agonists, orexin antagonists, TNF (tumor necrosis factor) agonists, CRF (corticotropin releasing factor) agonists, CRF BP (corticotropin releasing factor binding protein) antagonists, urocortin agonists, β 3 adrenergic agonists such as CL-316243, AJ-9677, GW-0604, LY362884, LY377267 or AZ-40140, MSH (melanocyte-stimulating hormone) agonists, MCH (melanocyte-concentrating hormone) antagonists, CCK (cholecystokinin) agonists, serotonin reuptake inhibitors (fluoxetine, seroxat or citalopram), serotonin and norepinephrine reuptake inhibitors, 5HT (serotonin) agonists, bombesin agonists, galanin antagonists, growth hormone, growth factors such as prolactin or placental lactogen, growth hormone releasing compounds, TRH (thyreotropin releasing hormone) ago-

30

35

nists, UCP 2 or 3 (uncoupling protein 2 or 3) modulators, leptin agonists, DA (dopamine) agonists (bromocriptin, doprexin), lipase/amylase inhibitors, PPAR modulators, RXR modulators, TR β agonists, adrenergic CNS stimulating agents, AGRP (agouti related protein) inhibitors, H3 histamine antagonists such as those disclosed in WO 00/42023, WO 00/63208 and
5 WO 00/64884, which are incorporated herein by reference, exendin-4, GLP-1 agonists and ciliary neurotrophic factor. Further antiobesity agents are bupropion (antidepressant), topiramate (anticonvulsant), ecopipam (dopamine D1/D5 antagonist), naltrexone (opioid antagonist), and peptide YY₃₋₃₆ (Batterham et al, Nature 418, 650-654 (2002)).

In one embodiment, the antiobesity agent is leptin.

10 In one embodiment, the antiobesity agent is peptide YY₃₋₃₆.

In one embodiment, the antiobesity agent is a serotonin and norepinephrine reuptake inhibitor eg sibutramine.

In one embodiment, the antiobesity agent is a lipase inhibitor eg orlistat.

In one embodiment, the antiobesity agent is an adrenergic CNS stimulating agent eg
15 dexamphetamine, amphetamine, phentermine, mazindol phendimetrazine, diethylpropion, fenfluramine or dexfenfluramine.

Furthermore, in the uses and methods of the present invention, the compound involved may be administered in combination with one or more antihypertensive agents. Examples of antihypertensive agents are β -blockers such as alprenolol, atenolol, timolol, pin-
20 dolol, propranolol and metoprolol, ACE (angiotensin converting enzyme) inhibitors such as benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril and ramipril, calcium channel blockers such as nifedipine, felodipine, nicardipine, isradipine, nimodipine, diltiazem and verapamil, and α -blockers such as doxazosin, urapidil, prazosin and terazosin. Further reference can be made to Remington: The Science and Practice of Pharmacy, 19th Edition, Gen-
25 naro, Ed., Mack Publishing Co., Easton, PA, 1995.

It should be understood that any suitable combination of the compounds according to the invention with diet and/or exercise, one or more of the above-mentioned compounds and optionally one or more other active substances are considered to be within the scope of the present invention.

30 The present invention also provides pharmaceutical compositions comprising as an active ingredient, at least one compound, preferably in a pharmacologically effective amount, more preferably in a therapeutically effective amount, suitable for any of the uses according to the present invention together with one or more pharmaceutically acceptable carriers or excipients.

The pharmaceutical composition is preferably in unit dosage form, comprising from about 0.05 mg to about 1000 mg, preferably from about 0.1 mg to about 500 mg and especially preferred from about 0.5 mg to about 200 mg of a compound suitable for any of the uses described above.

5 PHARMACEUTICAL COMPOSITIONS

The compounds for use according to the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients, in either single or multiple doses. The pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 20th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 2000.

The pharmaceutical compositions may be specifically formulated for administration by any suitable route such as the oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route, the oral route being preferred. It will be appreciated that the preferred route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient chosen.

Pharmaceutical compositions for oral administration include solid dosage forms such as hard or soft capsules, tablets, troches, dragees, pills, lozenges, powders and granules. Where appropriate, they can be prepared with coatings such as enteric coatings or they can be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art.

Liquid dosage forms for oral administration include solutions, emulsions, aqueous or oily suspensions, syrups and elixirs.

Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use. Depot injectable formulations are also contemplated as being within the scope of the present invention.

Other suitable administration forms include suppositories, sprays, ointments, cremes, gels, inhalants, dermal patches, implants etc.

A typical oral dosage is in the range of from about 0.001 to about 100 mg/kg body weight per day, preferably from about 0.01 to about 50 mg/kg body weight per day, and more preferred from about 0.05 to about 10 mg/kg body weight per day administered in one or more dosages such as 1 to 3 dosages. The exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.

The formulations may conveniently be presented in unit dosage form by methods known to those skilled in the art. A typical unit dosage form for oral administration one or more times per day such as 1 to 3 times per day may contain from 0.05 to about 1000 mg, preferably from about 0.1 to about 500 mg, and more preferred from about 0.5 mg to about 200 mg.

For parenteral routes such as intravenous, intrathecal, intramuscular and similar administration, typically doses are in the order of about half the dose employed for oral administration.

The present invention also encompasses pharmaceutically acceptable salts of the compounds suitable for use according to the present invention. Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts. Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like. Representative examples of suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pantoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference. Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like. Examples of ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.

Also intended as pharmaceutically acceptable acid addition salts are the hydrates which the present compounds are able to form.

The compounds for use according to the present invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof. Examples are an acid addition salt of a compound having the utility of a free base and a base addition salt of a compound having the utility of a free acid. The term "pharmaceutically acceptable salts" refers to non-toxic salts of the compounds for use according to the present invention which salts are generally prepared by reacting the free base with a suitable organic or inorganic acid or by reacting the acid with a suitable organic or inorganic base. When a compound for use according to the present invention contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of the compound with a chemical equivalent of a pharmaceutically acceptable acid. When a compound for use according to the present invention, contains a free acid such salts are prepared in a conventional manner by treating a solution or suspension of the compound with a chemical equivalent of a pharmaceutically acceptable base. Physiologically acceptable salts of a compound with a hydroxy group include the anion of said compound in combination with a suitable cation such as sodium or ammonium ion. Other salts which are not pharmaceutically acceptable may be useful in the preparation of compounds of the invention and these form a further aspect of the invention.

For parenteral administration, solutions of the compounds for use according to the present invention in sterile aqueous solution, aqueous propylene glycol or sesame or peanut oil may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. The aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.

Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solution and various organic solvents. Examples of solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose. Examples of liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene and water. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The pharmaceutical compositions formed by combining the compounds for use according to the present invention and the pharmaceutically acceptable carriers are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration. The formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient. Furthermore, the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.

Compositions intended for oral use may be prepared according to any known method, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents, and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically-acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch or alginic acid; binding agents, for example, starch, gelatine or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in U.S. Patent Nos. 4,356,108; 4,166,452; and 4,265,874, incorporated herein by reference, to form osmotic therapeutic tablets for controlled release.

Formulations for oral use may also be presented as hard gelatine capsules where the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or a soft gelatine capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions may contain the compound for use according to the present invention in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide such as lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyl-eneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial es-

ters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.

5 Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as a liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions
10 may be preserved by the addition of an anti-oxidant such as ascorbic acid.

 Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active compound in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavouring, and colouring agents may also be present.
15

 The pharmaceutical compositions comprising compounds for use according to the present invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example a liquid paraffin, or a mixture thereof. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain
20 sweetening and flavouring agents.
25

 Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known methods using suitable dispersing or wetting agents and suspending agents described above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition,
30 sterile, fixed oils are conveniently employed as solvent or suspending medium. For this
35

purpose, any bland fixed oil may be employed using synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

The compositions may also be in the form of suppositories for rectal administration of the compounds of the invention. These compositions can be prepared by mixing the drug
5 with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will thus melt in the rectum to release the drug. Such materials include cocoa butter and polyethylene glycols, for example.

For topical use, creams, ointments, jellies, solutions of suspensions, etc., containing the compounds of the invention are contemplated. For the purpose of this application, topical
10 applications shall include mouth washes and gargles.

The compounds of the present invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes may be formed from a variety of phospholipids, such as cholesterol, stearylamine, or phosphatidylcholines.

15 In addition, some of the compounds of the present invention may form solvates with water or common organic solvents. Such solvates are also encompassed within the scope of the invention.

Thus, in a further embodiment, there is provided a pharmaceutical composition comprising a compound for use according to the present invention, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents.
20

If a solid carrier is used for oral administration, the preparation may be tableted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge. The amount of solid carrier will vary widely but will usually be from about 25 mg
25 to about 1 g. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.

A typical tablet that may be prepared by conventional tableting techniques may contain:

30	Core:	
	Example 19	5.0 mg
	Lactosum Ph. Eur.	67.8 mg
	Cellulose, microcryst. (Avicel)	31.4 mg
	Amberlite®IRP88*	1.0 mg
35	Magnesii stearas Ph. Eur.	q.s.

Coating:

Hydroxypropyl methylcellulose	approx.	9 mg
Mywacett 9-40 T**	approx.	0.9 mg


5

* Polacrillin potassium NF, tablet disintegrant, Rohm and Haas.

** Acylated monoglyceride used as plasticizer for film coating.

10 If desired, the pharmaceutical composition comprising a compound for use according to the present invention may comprise a compound for use according to the present invention in combination with further active substances such as those described in the foregoing.

The present invention also provides methods for the preparation of compounds for use according to the present invention. The compounds can be prepared readily according to the following general procedures (in which all variables are as defined before, unless so
15 specified) using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but are not mentioned in greater detail.

GENERAL PROCEDURES**General procedure (A): Preparation of compounds of the general formula I**

20


(I)

Compounds of the general formula (I), wherein A, R¹, R², R³, and R⁴ are as described above, are aryl or heteroaryl derivatives with electron withdrawing groups that make the compounds of formula (I) more acidic than the corresponding unsubstituted phenolic aryl
25 or heteroaryl.

The compounds of formula (I) may be prepared from the corresponding phenolic aryls or heteroaryl by e.g. nitration of the corresponding phenols. The resulting nitrophenols may be converted to many halogenated derivatives by conversion to aniline, diazotization or by other methods known to the person skilled in the art. Other methods of substituting phe-

54

nolic aryls and heteroaryl with substituents like R^1 , R^2 , R^3 , and R^4 are known to the person skilled in the art




(Ia)

- 5 Compounds of the general formula (Ia), a subgroup of the compounds of general formula (I), wherein R^2 , R^3 , and R^4 are as described above, are phenol derivatives with electro withdrawing groups that make the compounds of formula (Ia) more acidic than phenol.

- The compounds of formula (Ia) may be prepared from the corresponding phenols by treatment with a mixture of sulphuric acid and nitric acid by methods which are known by those skilled in the art and described in Vogels *Textbook of practical organic chemistry* (5th ed Longman Scientific and Technical, 1989).


General procedure (B)



(II)

- 15 Compounds of the general formula (II), wherein A^1 , A^2 , R^5 , and n are as described above, may be prepared from bis-phenolic aryls or heteroaryl by nitration. Bis-phenolic aryls or heteroaryl are available by a number of routes, including treatment of aldehydes, ketones or alkenes with phenol in the presence of suitable catalysts or in protected versions with Grignard reagents treated with ketones, aldehydes or esters.

20 General procedure (C)




(III)

Compounds of the general formula (III), wherein R^6 , R^7 , R^8 , and R^9 are as described above, are phenol derivatives with electro withdrawing groups that make the compounds of formula (Ia) more acidic than phenol.


- The compounds of formula (III) may be prepared from the corresponding phenols by
 5 treatment with a mixture of sulphuric acid and nitric acid by methods which are known by those skilled in the art and described in *Vogels Textbook of practical organic chemistry*.

General procedure (D)




(IV)

- 10 Compounds of the general formula (IV), wherein R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , and R^{18} are as described above, may be prepared from a substituted benzoic acid ($X=OH$) or a benzoyl chloride ($X=Cl$). In the former case reagents such phosphorous trichloride, phosphorous pentachloride, phosphorous tribromide or oxalyl chloride is employed and solvents such as collidine, chlorobenzene or toluene. The methods are described in e.g. Brown et. al.
 15 (J. Med. Chem. 1985, 143-146).





56

General procedur (E)

(V)


- Compounds of general formula (V), wherein R^{19} , R^{20} , R^{21} , R^{22} , and R^{23} are as described above, may be prepared by treating commercially available 4-methylphenols with N-bromosuccinimide and a radical initiator such as benzoylperoxide in a solvent such as carbon tetrachloride for 1 to 24 hours under reflux. The 4-bromomethylphenols produced this way is treated with a trialkylphosphine, such as tripropylphosphine, or a trialkylphosphine, such as triphenylphosphine, in a solvent such as tetrahydrofuran or acetone. The salt can eventually be precipitated with a solvent such as diethylether or hexane.

**General procedure (F)**

(VI)


- Compounds of the general formula (VI), wherein R^{24} , R^{25} , and R^{26} are as described above and X is $=C(R^{52})-$, wherein R^{52} are as described above, may be prepared from the corresponding aldehyde which may be commercially available (e.g. 3,5-di-tert-butyl-4-

hydroxybenzaldehyde) or which can be made by reactions known to the person skilled in the art, such as exemplified in Vogels "Textbook of organic chemistry", and which aldehyde by a Knoevenagel reaction with a suitable substrate such as malonodinitrile can be made to react to generate compounds of the general formula (VI) by heating in a solvent such as toluene or benzene with ammonium acetate as catalyst and isolation by methods known by those skilled in the art.




Compounds of the general formula (VI), wherein R²⁴, R²⁵, and R²⁶ are as described above and X is =N-, may be prepared from the corresponding aldehyde and a commercially available primary amine such as exemplified in Vogels "Textbook of organic chemistry".

General procedure (G)



Compounds of general formula (VII), wherein R²⁷, R²⁸, R²⁹, R³⁰, and R³¹ are as described above, may be prepared by introducing R³¹ via the corresponding aldehyde, which may be commercially available (e.g. indole-3-carboxaldehyde) or which can be made by reactions known to the person skilled in the art, such as exemplified in Vogels Textbook of practical organic chemistry and which aldehyde by a Knoevenagel reaction with a suitable substrate such as malononitrile can be made to react to generate compounds of formula (VII) by heating in a solvent such as toluene or benzene with ammonium acetate as catalyst and isolation by methods known by those skilled in the art. Alternatively, the electro withdrawing group R³¹ may be present in the ring forming step using methods described in Eicher et al. "The chemistry of heterocycles" (Thieme, 1995, 1 ed.) and references herein.

58



Such compounds may also be prepared by classical pyrrole syntheses such as the Hantzsch and Knorr procedures (see "The chemistry of Heterocycles" Eicher et al, Thieme) or by the methods described in Kuhn et al. *Phytochemicals for Pest Control*, ACS Symposium Series 658, 194-205 (1997), and Kuhn et al, *Pesticide Science* 41, 279-286 (1994).

The following examples show compounds for use as a chemical uncoupler as described herein as well as comparative examples showing comparative compounds.

10

HPLC-MS (Method A)

15 The following instrumentation is used:

- Hewlett Packard series 1100 G1312A Bin Pump
- Hewlett Packard series 1100 Column compartment
- Hewlett Packard series 1100 G1315A DAD diode array detector
- Hewlett Packard series 1100 MSD
- 20 ◦ Sedere 75 Evaporative Light Scattering detector

The instrument is controlled by HP Chemstation software.

The HPLC pump is connected to two eluent reservoirs containing:

A: 0.01% TFA in water

B: 0.01% TFA in acetonitrile

25 The analysis is performed at 40°C by injecting an appropriate volume of the sample (preferably 1 µl) onto the column which is eluted with a gradient of acetonitrile.

The HPLC conditions, detector settings and mass spectrometer settings used are giving in the following table.

Column: Waters Xterra MS C-18 X 3 mm id 5 µm

Gradient: 5% - 100% acetonitrile linear during 7.5 min at 1.5ml/min

Detection: 210 nm (analogue output from DAD (diode array detector))

ELS (analogue output from ELS)

MS ionisation mode API-ES


5 Scan 100-1000 amu step 0.1 amu

After the DAD the flow is divided yielding approx 1 ml/min to the ELS and 0.5 ml/min to the MS.

EXAMPLES

Example 1 (General procedure (B))


10 4,4-Bis-(4-hydroxy-3-nitrophenyl)-valeric acid



The title compound may be prepared according to General procedure B or purchased from Aldrich Chemical Company, Inc., catalogue number F209216.

Example 2 (General procedure (A))


15 4-Methoxy-2-nitrophenol



The title compound may be prepared according to General procedure A or purchased from Aldrich Chemical Company, Inc., catalogue number 1568-70-3.

Example 3 (General procedure (A))


4-Hydroxy-3-nitroacetophenone



The title compound may be prepared according to General procedure A or purchased from Aldrich Chemical Company, Inc., catalogue number 6622-56-1.

Example 4 (General procedure (A))


7-Hydroxy-4-methyl-8-nitro-chromen-2-one



The title compound may be prepared according to General procedure A or purchased from Lancaster Synthesis Ltd., catalogue number F7896.

Example 5 (General procedure (D))


3-Tert-butyl-5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy-6-methyl-benzamide



The title compound may be prepared according to General procedure D or purchased from Sigma-Aldrich Chemie GmbH, catalogue number R548758.

Example 6 (General procedure (D))


N-1-[4-cyano-3-(trifluoromethyl)phenyl]-3,5-di(trifluoromethyl)benzamide



The title compound may be prepared according to General procedure D or purchased from Maybridge plc, catalogue number RDR03708.

Example 7 (General procedure (D))


N-(4-cyanophenyl)benzamide



The title compound may be prepared according to General procedure D or purchased from Maybridge plc, catalogue number HTS05127.

Example 8 (General procedure (D))


2'-Chloro-1-hydroxy-4'-nitro-2-naphthanilide



The title compound may be prepared according to General procedure D or purchased from Aldrich Chemical Company, Inc., catalogue number S62,938-3.

Example 9 (General procedure (D))


N-(2-chloro-4-bromophenyl)-5-bromosalicylanilide



The title compound may be prepared according to General procedure D or purchased from Maybridge plc, catalogue number BTB 12821.


Example 10 (General procedure (D))

N-(2-chloro-4-nitrophenyl)-3-tert-butyl-6-methylsalicylanilide




3-tert-Butyl-6-methylsalicylic acid (5.0 g, 24 mmol) and 2-chlor-4-nitroanilin (4.1 g; 24 mmol) were dissolved in chlorobenzene (140 ml). Phosphoroxchloride (0.63 ml) was added and the mixture was refluxed 4.5 hours under nitrogen atmosphere. The solvent was removed in vacuo and the residue crystallized from acetic acid yielding 6.3 g of the title compound.

¹H-NMR: (CDCl₃, 400 MHz): 1.43 (s, 9H); 2.65 (s, 3H); 6.76 (d, 1H); 7.34 (d, 1H); 8.22 (dd, 1H); 8.42 (d, 1H); 8.47 (s (br); 1H); 8.86 (d, 1H); 10.3 (s (br); 1H).

Example 11 (General procedure (E))(3,5-Di-*tert*-butyl-4-hydroxybenzyl)triphenylphosphonium bromide

The title compound may be prepared according to General procedure E or purchased from Sigma-Aldrich Chemie GmbH, catalogue number S545813.

Example 12 (General procedure (E))(3,5-Di-*tert*-butyl-4-hydroxybenzyl)tricyclohexylphosphonium bromide

The title compound may be prepared according to General procedure E.


- 10 2,6-Di-*tert*-butyl-4-methylphenol is treated with 1 equivalent of N-bromo-succinimide in tetrachloromethane under reflux for 1 hour in the presence of 0.1 equivalent of benzoylperoxide. After evaporation of the solvent, 2,6-di-*tert*-butyl-4-bromomethylphenol is isolated using gradient elution on silica gel with heptane/methylene chloride as eluent. The crude 2,6-di-*tert*-butyl-4-bromomethylphenol (1 equivalent) is dissolved in dry diethyl ether (10% solution) and
- 15 treated with a 10% solution of trialkyl- or triarylphosphine in diethyl ether. After 1 hour of stir-

ring, crystalline material is filtered off.

LCMS m/z : 499.5 (M+H)⁺

Example 13 (General procedure (E))

(3,5-Di-*tert*-butyl-4-hydroxybenzyl)tributylphosphonium bromide



5

The title compound may be prepared according to General procedure E.

2,6-Di-*tert*-butyl-4-methylphenol is treated with 1 equivalent of N-bromo-succinimide in tetra-

chloromethane under reflux for 1 hour in the presence of 0.1 equivalent of benzoylperoxide. After evaporation of the solvent, 2,6-di-*tert*-butyl-4-bromomethylphenol is isolated using gra-


10

dent elution on silica gel with heptane/methylene chloride as eluent. The crude 2,6-di-*tert*-butyl-4-bromomethylphenol (1 equivalent) is dissolved in dry diethyl ether (10% solution) and treated with a 10% solution of tributylphosphine in diethyl ether. After 1 hour of stirring, crystalline material is filtered off.

LCMS m/z : 421.3 (M+H)⁺

15 **Example 14** (General procedure (E))

(3,5-Di-*tert*-butyl-4-hydroxybenzyl)trioctylphosphonium bromide



The title compound may be prepared according to General procedure E.

2,6-Di-*tert*-butyl-4-methylphenol is treated with 1 equivalent of N-bromo-succinimide in tetra-

20


chloromethane under reflux for 1 hour in the presence of 0.1 equivalent of benzoylperoxide. After evaporation of the solvent, 2,6-di-*tert*-butyl-4-bromomethylphenol is isolated using gra-

dient elution on silica gel with heptane/methylene chloride as eluent. The crude 2,6-di-*tert*-butyl-4-bromomethylphenol (1 equivalent) is dissolved in dry diethyl ether (10% solution) and treated with a 10% solution of trioctylphosphine in diethyl ether. After 1 hour of stirring, the ether is decanted off, the oil triturated with ether and the remaining oil is dried *in vacuo*.

5 LCMS m/z: 591.0 (M+H)⁺

Example 15 (General procedure (F))

2-Cyano-3-(3,5-di-*tert*-butyl-4-hydroxyphenyl)-acrylic acid ethyl ester




The title compound may be prepared according to General procedure F or purchased from Sigma-Aldrich Chemie GmbH, catalogue number S482102.

10

Example 16 (General procedure (F))

2-(3,5-Di-*tert*-butyl-4-hydroxy-benzylidene)-malonic acid diethyl ester




The title compound may be prepared according to General procedure F or purchased from Sigma-Aldrich Chemie GmbH, catalogue number S482196.

15

Example 17 (General procedure (F))


2-Amino-S-[(3,5-di-tert-butyl-4-hydroxybenzylidene)-amino]-but-2-enedinitrile



The title compound may be purchased from Menai, catalogue number DW 150.

5 **Example 18** (General procedure (F))


2-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-indan-1,3-dione



The title compound may be prepared according to General procedure F or purchased from Maybridge plc, catalogue number LJ 902.

Example 19 (General procedure (G))


2-[[2-(4-Chlorophenyl)-1H-indol-3-yl]methylene]malononitrile



The title compound may be prepared according to General procedure G or purchased from Maybridge plc, catalogue number SEW 03041.

Example 20 (General procedure (G))


2-(4-Chlorophenyl)-indole



The title compound may be prepared according to General procedure G or purchased from Maybridge plc, catalogue number RDR 01154.

Example 21


N-(2,4,5-trichlorophenyl)salicylanilide



The title compound may purchased from Maybridge plc, catalogue number RDR 01398.

Example 22 (General procedure (G))


2,3-Dimethyl-5-cyano-7-ethylindole



The title compound may be purchased from Aldrich Chemical Company, Inc., catalogue number 30,205-8.

Example 23 (General procedure (G))


4-Bromo-2-(4-chlorophenyl)-5-trifluoromethyl-1H-pyrrole-3-carbonitrile




This compound was prepared as described in Kameshwaran, Synthesis 5, 530 (1997).

Example 24

N-(3-Cyano-4-phenylsulfanyl-phenyl)-3-trifluoromethyl-benzamide




This compound is commercially available from Bionet (cat nr. 11K-627S).

Example 252,6-Di-*t*-butyl-4-(2',2'-dicyanovinyl)phenol


The title compound may be prepared according to General procedure F or purchased from Biomol research Laboratories Inc., catalogue number EI-215.

Comparative Example 26

2,4-Dinitrophenol



Available from Sigma-Aldrich Chemie GmbH, catalogue number D-7004.

Comparative Example 27Carbonylcyanide *p*-trifluoromethoxy-phenylhydrazone


Available from Sigma-Aldrich Chemie GmbH, catalogue number F-86,184-7.

New examples for patent 6433.0000.

70

Example 28.(General procedure (G))

2-(5,7-Dimethyl-1H-indol-3-ylmethylene)-malononitrile




This compound is commercially available from Salor, R43,763-8.

5

Example 29.(General procedure (G))

2-(5-Bromo-1H-indol-3-ylmethylene)-malononitrile




10

This compound is commercially available from Salor, R55,004-3.

Example 30.(General procedure (G))

2-((5-Chloro-1H-indol-3-yl)methylene)malononitrile




15

This compound is commercially available from Salor, R94,793-8.

Example 31.(General procedure (G))


20 2-((5-Methyl-1H-indol-3-yl)methylene)malononitrile

71



This compound is commercially available from Salor, R94-816-0.


- 5 **Example 32.**(General procedure (G))
2-((5-Methyl-1H-indol-3-yl)methylene)malononitrile.



This compound is commercially available from Maybridge, cat. no: RDR01178.

10

- Example 33** (General procedure (G))
2-(2-Phenyl-3-indolylmethylene)-malononitrile.




- 15 The title compound was prepared from 2-phenyl-3-formylindole and malonitrile in ethanol using a catalytic amount of piperidine.

^1H NMR (400 MHz, CHLOROFORM-D): δ ppm 7.40 (m, 2 H) 7.49 (m, 3 H) 7.60 (m, 3 H) 7.81 (s, 1 H) 8.25 (m, 1 H) 9.02 (s, 1 H); HPLC-MS (Method A): m/z = 270 (M+1); R_t = 4.72 min.

72

Example 34 (General procedure (G))

2-(2-Chloro-1H-indol-3-ylmethylene)-malononitrile




The title compound was prepared from 2-chloro-3-formylindol and malonitrile in
5 ethanol using a catalytic amount of piperidine.

^1H NMR ($\text{DMSO}-d_6$): δ ppm 7.33 (m, 2 H) 7.48 (d, 1 H) 8.07 (d, 1 H) 8.19 (s, 1 H)
13.75 (s, 1 H); HPLC-MS (Method A): m/z = 228, 230 ($\text{M}+1$); R_t = 3.41 min.

10

Example 35 (General procedure (G))

2-(5-Nitro-1H-indol-3-ylmethylene)-malononitrile.



The title compound was prepared from 5-nitro-3-formylindol and malonitrile in etha-
15 nol using a catalytic amount of piperidine.


^1H NMR ($\text{DMSO}-d_6$): δ ppm 7.77 (d, $J=8.67$ Hz, 1 H) 8.17 (dd, $J=8.67$, 2.26 Hz, 1 H)
8.72 (s, 1 H) 9.01 (s, 1 H) 9.14 (d, $J=2.26$ Hz, 1 H) 13.02 (m, 1 H); HPLC-MS (Method A):
 m/z = 239 ($\text{M}+1$); R_t = 3.51 min.

20

73

Example 36 (General procedure (G))

2-(2-Methyl-5-nitro-1H-indol-3-ylmethylene)-malononitrile.




The title compound was prepared from 2-methyl-5-nitro-3-formylindol and malonitrile
 5 in ethanol using a catalytic amount of piperidine.

¹H NMR (DMSO-*d*₆): δ ppm 7.63 (d, *J*=9.04 Hz, 1 H) 8.14 (dd, *J*=9.04, 2.26 Hz, 1 H)
 8.48 (s, 1 H) 9.05 (d, *J*=2.26 Hz, 1 H) 13.17 (m, 1 H); HPLC-MS (Method A): *m/z* = 253
 (M+1); *R*_t = 3.51 min.

10

15 **Example 37** (General procedure (D))

3-Bromo-5-tert-butyl-N-(2-chloro-4-nitro-phenyl)-6-hydroxy-2-methyl-benzamide.




The title compound was prepared from 5-bromo-3-tert-butyl-6-methylsalicylic acid
 and 2-chloro-4-nitroanilin.

20

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.41 (m, 9 H) 2.64 (s, 3H) 7.58 (s, 1 H) 8.25
 (dd, *J*=9.10, 2.53 Hz, 1 H) 8.32 (s, 1 H) 8.35 (d, *J*=2.53 Hz, 1 H) 8.85 (d, *J*=9.10 Hz, 1 H)
 9.47 (s, 1 H); HPLC-MS (Method A): *m/z* = 443(M+1); *R*_t = 5.57 min.

Example 38 (General procedure (D))

N-(2-Chloro-4-nitro-phenyl)-2-hydroxy-3-isopropyl-benzamide.




5 The title compound was prepared from 3-isopropylsalicylic acid and 2-chlor-4-nitroanilin.

$^1\text{H-NMR}$: (CDCl_3 , 400 MHz): δ ppm 1.26 (d, 6 H) 6.93 (t, $J=7.36$ Hz, 1 H) 7.42 (dd, $J=18.4$ Hz, $J=7.36$ Hz, 2 H) 8.20 (d, $J=9.2$ Hz, 1 H) 8.35 (s, 1 H) 8.75 (d, $J=9.2$ Hz, 1H) 8.82
10 (s, 1H) 11.77 (s, 1H); HPLC-MS (Method A): m/z = 335, 337(M+1); R_t = 5.18 min.

Example 39 (General procedure (D))

N-(2-Chloro-4-nitro-phenyl)-2-hydroxy-3-isopropyl-6-methyl-benzamide.




15

The title compound was prepared from 3-isopropyl-6-methylsalicylic acid and 2-chlor-4-nitroanilin.

$^1\text{H-NMR}$: (CDCl_3 , 400 MHz): δ ppm 1.24 (d, 6 H) 2.68 (s, 3H) 6.79 (d, $J=9.2$ Hz, 1
20 H) 7.25 (s, 1 H) 8.24 (dd, 1 H) 8.36 (s, 1 H) 8.54 (s, 1 H) 8.85 (d, $J=9.2$ Hz 1H) 10.25 (s, 1H)
); HPLC-MS (Method A): m/z = 349, 351(M+1); R_t = 4.87 min.

Example 40 (General procedure (D))

3,5-Di-tert-butyl-N-(2-chloro-4-nitro-phenyl)-2-hydroxy-benzamide.



5


The title compound was prepared from 3,5-di-tertbutylsalicylic acid and 2-chlor-4-nitroanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.36 (s, 9 H) 1.44 (s, 9 H) 7.39 (s, 1 H) 7.58 (s, 1 H) 8.23 (m, Hz, 1 H) 8.35 (m, 1 H) 8.76 (m, 1H) 8.86 (s, 1H) 11.89 (s, 1H).

10

Example 41 (General procedure (D))

3-Bromo-N-(2-chloro-4-nitro-phenyl)-6-hydroxy-5-isopropyl-2-methyl-benzamide.



15


The title compound was prepared from 5-bromo-3-isopropyl-6-methylsalicylic acid and 2-chlor-4-nitroanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.25 (d, 6 H) 2.67 (m, 3 H) 7.50 (s, 1 H) 8.25 (m, 1 H) 8.35 (m, 1 H) 8.87 (m, 1 H).

20

Example 42 (General procedure (D))

3-tert-Butyl-5-chloro-N-(4-chloro-3-trifluoromethyl-phenyl)-2-hydroxy-6-methyl-benzamide.




5 The title compound was prepared from 5-chloro-3-tert-butyl-6-methylsalicylic acid and 3-trifluoromethyl-4-chloroanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.40 (s, 9 H) 2.52 (s, 3 H) 7.39 (s, 1 H) 7.60 (m, 1 H) 7.66 (m, 1 H) 7.73 (s, 1 H) 8.37 (d, *J* = 9.2, 1 H); HPLC-MS (Method A): *m/z* = 420, 10 422(*M*+1); *R*_t = 5.63 min.

Example 43 (General procedure (D))

3-tert-Butyl-5-chloro-N-(4-cyano-3-trifluoromethyl-phenyl)-2-hydroxy-6-methyl-benzamide.




15

 The title compound was prepared from 5-chloro-3-tert-butyl-6-methylsalicylic acid and 4-cyano-3-trifluoromethylanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.40 (s, 9 H) 2.53 (s, 3 H) 7.39 (s, 1 H) 7.66 (s, 20 1 H) 7.86 (d, *J*=8,3 Hz, 1 H) 8.97 (d, *J*=8,3 Hz, 1 H) 8.05 (s, 1 H) 9.05 (s, 1H).

Example 44 (General procedure (D))

2-Hydroxy-biphenyl-3-carboxylic acid (2-chloro-4-nitro-phenyl)-amide.




- 5 The title compound was prepared from 3-phenylsalicylic acid and 2-chlor-4-nitroanilin.

$^1\text{H-NMR}$: (CDCl_3 , 400 MHz): δ ppm 7.07 (m, 1 H) 7.40 (m, 1 H) 7.48 (m, 2 H) 7.58 (m, 3 H) 7.69 (m, 1 H) 8.22 (m, 1 H) 8.35 (s, 1H) 8.79 (m, 1H) 9.13 (m, 1H) 11.20 (s, 1H);

- 10 HPLC-MS (Method A): m/z = 369, 371($M+1$); R_t = 5.05 min.

Example 45 (General procedure (D))

3-tert-Butyl-N-(2-chloro-4-nitro-phenyl)-2-hydroxy-5-methyl-benzamide.



- 15


The title compound was prepared from 3-tert-butyl-5-methylsalicylic acid and 2-chlor-4-nitroanilin.

- 20 $^1\text{H-NMR}$: (CDCl_3 , 400 MHz): δ ppm 1.42 (s, 9 H) 2.36 (s, 3 H) 7.19 (s, 1 H) 7.32 (s, 1 H) 8.22 (m, 1 H) 8.37 (m, 1 H) 8.74 (m, 1H) 8.78 (s, 1H) 11.82 (s, 1H).

78

Example 46 (General procedure (D))

N-(2-Chloro-4-nitro-phenyl)-2-hydroxy-6-isopropyl-3-methyl-benzamide.




The title compound was prepared from 3-methyl-6-isopropylsalicylic acid and 2-chlor-4-nitroanilin.

$^1\text{H-NMR}$: (CDCl_3 , 400 MHz): δ ppm 1.33 (d, 6 H) 2.25 (s, 3 H) 3.28 (m, 1 H) 6.90 (d, $J=7.4$ Hz, 1 H) 7.23 (d, $J=7.4$ Hz, 1 H) 7.82 (s, 1H) 8.22 (m, 2H) 8.33 (s, 1H) 8.85 (m, 1H); HPLC-MS (Method A): m/z = 349, 351($M+1$); R_t = 4.85 min.

10

Example 47 (General procedure (D))

N-(3,5-Bis-trifluoromethyl-phenyl)-3-tert-butyl-5-chloro-2-hydroxy-6-methyl-benzamide.




The title compound was prepared from 3-tert-butyl-5-chloro-6-methylsalicylic acid and 3,5-Bis-trifluoromethylanilin.

$^1\text{H-NMR}$: (CDCl_3 , 400 MHz): δ ppm 1.40 (s, 9 H) 2.56 (s, 3 H) 7.39 (s, 1 H) 7.69 (s, 1 H) 7.70 (m, 1 H) 8.10 (m, 2 H); HPLC-MS (Method A): m/z = 397($M+1$); R_t = 4.75 min.

20

Example 48 (General procedure (D))

3-tert-Butyl-5-chloro-N-(2-fluoro-5-trifluoromethyl-phenyl)-2-hydroxy-6-methyl-benzamide.




The title compound was prepared from 3-tert-butyl-5-chloro-6-methylsalicylic acid
5 and 2-fluoro-5-trifluoromethylanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.40 (s, 9 H) 2.57 (s, 3 H) 7.38 (s, 1 H) 7.45 (m, 1 H) 7.78 (m, 1 H) 8.82 (m, 1 H).

10 **Example 49** (General procedure (D))

3-tert-Butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-benzamide.




The title compound was prepared from 3-tert-butyl-5-chloro-6-methylsalicylic acid
15 and 4-nitro-3-trifluoromethylanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.40 (s, 9 H) 2.53 (s, 3 H) 7.39 (s, 1 H) 7.70 (m, 1 H) 8.04 (m, 2 H) 9.03 (s, 1 H). HPLC-MS (Method A): *m/z* = 431, 433 (M+1); R_t = 5.4 min.

Example 50 (General procedure (D))

3-tert-Butyl-5-chloro-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide.




The title compound was prepared from 3-tert-butyl-5-chloro-6-methylsalicylic acid
5 and 4-nitro-2-trifluoromethylanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.41 (s, 9 H) 2.53 (s, 3 H) 7.42 (s, 1 H) 8.03 (s, 1 H) 8.51 (m, 1 H) 8.59 (m, 1 H) 8.89 (m, 1 H) 9.30 (s, 1 H); HPLC-MS (Method A): m/z = 431, 433 (M+1); R_t = 5.4 min.

10

Example 51 (General procedure (D))

3-Bromo-5-tert-butyl-N-(2-chloro-4-cyano-phenyl)-6-hydroxy-2-methyl-benzamide.




15 The title compound was prepared from 3-tert-butyl-5-bromo-6-methylsalicylic acid
and 2-chloro-4-cyanoanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.41 (s, 9 H) 2.61 (s, 3 H) 7.57 (s, 1 H) 7.68 (m, 1 H) 7.74 (m, 1 H) 8.23 (s, 1 H) 8.78 (m, 1 H) 9.48 (s, 1 H).); HPLC-MS (Method A): m/z =
20 430, 432, 434 (M+1); R_t = 5.9 min.

Example 52 (General procedure (D))

3-Bromo-5-tert-butyl-N-(2-chloro-5-trifluoromethyl-phenyl)-6-hydroxy-2-methyl-benzamide.




The title compound was prepared from 3-tert-butyl-5-bromo-6-methylsalicylic acid
5 and 2-chloro-5-trifluoromethylanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.41 (s, 9 H) 2.63 (s, 3 H) 7.4 (m, 1 H) 7.54 (m, 2 H) 8.13 (s, 1 H) 8.90 (s, 1H) 9.57 (s, 1 H).

10 **Example 53** (General procedure (D))

3-Bromo-5-tert-butyl-N-(2,4-dichloro-phenyl)-6-hydroxy-2-methyl-benzamide.



The title compound was prepared from 3-tert-butyl-5-bromo-6-methylsalicylic acid
and 2,4-dichloroanilin.


15

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.4 (s, 9 H) 2.61 (s, 3 H) 7.33 (m, 1 H) 7.46 (m, 1 H) 7.55 (s, 1 H) 8.00 (s, 1H) 8.50 (m, 1 H) 9.60 (s, 1H).); HPLC-MS (Method A): m/z = 430, 432, 434 (M+1); R_t = 5.9 min.

20

Example 54 (General procedure (D))

3-Bromo-5-tert-butyl-N-(2,4-dichloro-6-nitro-phenyl)-6-hydroxy-2-methyl-benzamide.




The title compound was prepared from 3-tert-butyl-5-bromo-6-methylsalicylic acid
5 and 2,4-dichloro-6-nitroanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.40 (s, 9 H) 2.69 (s, 3 H) 7.56 (s, 1 H) 7.78 (m, 1 H) 7.97 (m, 2 H) 9.40 (s, 1H).); HPLC-MS (Method A): m/z = 497, 499, 501 (M+1); R_t = 5.9 min.

10

Example 55 (General procedure (D))

3-Bromo-5-tert-butyl-N-(2,6-dichloro-4-nitro-phenyl)-6-hydroxy-2-methyl-benzamide.




The title compound was prepared from 3-tert-butyl-5-bromo-6-methylsalicylic acid
15 and 2,6-dichloro-4-nitroanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.41 (s, 9 H) 2.71 (s, 3 H) 7.35 (s, 1 H) 7.58 (s, 1 H) 8.32 (m, 2 H) 9.40 (s, 1H).); HPLC-MS (Method A): m/z = 475, 477, 479 (M+1); R_t = 5.6 min.

Example 56 (General procedure (D))

3-Bromo-5-tert-butyl-N-{5-chloro-4-[(4-chloro-phenyl)-cyano-methyl]-2-methyl-phenyl}-6-hydroxy-2-methyl-benzamide.




- 5 The title compound was prepared from 3-tert-butyl-5-bromo-6-methylsalicylic acid and 5-chloro-4-[(4-chloro-phenyl)-cyano-methyl]-2-methylanilin.

$^1\text{H-NMR}$: (CDCl_3 , 400 MHz): δ ppm 1.41 (s, 9 H) 2.31 (s, 3 H) 2.60 (s, 3 H) 7.33 (m, 6 H) 7.54 (s, 1 H) 8.29 (s, 1H) 9.40 (s, 1 H); HPLC-MS (Method A): m/z = 559, 561, 563

- 10 ($M+1$); R_t = 5.92 min.

Example 57 (General procedure (D))

3-Bromo-6-hydroxy-5-isopropyl-2-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide.



- 15 The title compound was prepared from 3-isopropyl-5-bromo-6-methylsalicylic acid and 4-nitro-2-trifluoromethylanilin.


84

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.25 (d, 6H) 2.56 (s, 3H,) 7.52 (s, 1 H) 8.04 (s, 1 H) 8.51 (m, 1H) 8.59 (m, 1 H) 8.86 (m, 1H); HPLC-MS (Method A): m/z = 461, 463 (M+1); R_t = 4.9 min.

5

Example 58 (General procedure (D))

3-Bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide.




The title compound was prepared from 3-tert-butyl-5-bromo-6-methylsalicylic acid
10 and 4-nitro-2-trifluoromethylanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.41 (s, 9 H) 2.53 (s, 3 H) 7.58 (s, 1 H) 8.02 (s, 1 H) 8.52 (m, 1 H) 8.59 (m, 1 H) 8.89 (m, 1 H) 9.20 (s, 1H); HPLC-MS (Method A): m/z = 475, 477(M+1); R_t = 5.5 min. .

15

Example 59 (General procedure (D))

3-tert-Butyl-2-hydroxy-6-methyl-N-(4-nitro-2-trifluoromethyl-phenyl)-benzamide.




The title compound was prepared from 3-tert-butyl-6-methylsalicylic acid and 4-nitro-
20 2-trifluoromethylanilin.

$^1\text{H-NMR}$: (CDCl_3 , 400 MHz): δ ppm 1.43 (s, 9 H) 2.57 (s, 3 H) 6.75 (d, $J=7.36$ Hz, 1 H) 7.34 (d, $J=7.36$ Hz, 1 H) 8.18 (s, 1 H) 8.51 (m, 1 H) 8.59 (m, 1H) 8.83 (m, 1H) 10.24 (s, 1H).

5 **Example 60** (General procedure (D))

3-Bromo-N-(2-bromo-3,5-bis-trifluoromethyl-phenyl)-5-tert-butyl-6-hydroxy-2-methyl-benzamide.




10 The title compound was prepared from 3-tert-butyl-5-bromo-6-methylsalicylic acid and 2-bromo-3,5-bis-trifluoromethylanilin.

$^1\text{H-NMR}$: (CDCl_3 , 400 MHz): δ ppm 1.41 (s, 9 H) 2.65 (s, 3 H) 7.56 (s, 1 H) 7.35 (m, 1 H) 8.40 (s, 1 H) 9.13 (s, 1H) 9.35 (s, 1 H); HPLC-MS (Method A): m/z = 576, 578, 580 ($M+1$); R_t = 6.1 min.

15

Example 61 (General procedure (D))

N-(2,5-Bis-trifluoromethyl-phenyl)-3-bromo-5-tert-butyl-6-hydroxy-2-methyl-benzamide.




The title compound was prepared from 3-tert-butyl-5-bromo-6-methylsalicylic acid and 2,5-bis-trifluoromethylanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.40 (s, 9 H) 2.56 (s, 3 H) 7.57 (m, 2 H) 7.83 (m, 2 H) 8.82 (s, 1 H) 9.35 (s, 1 H); HPLC-MS (Method A): m/z = 430, 432, 434 (M+1); R_t = 5.9 min.); HPLC-MS (Method A): m/z = 498, 500 (M+1); R_t = 5.8 min.

10 **Example 62** (General procedure (D))

3-Bromo-5-tert-butyl-N-(2,4-dichloro-6-trifluoromethyl-phenyl)-6-hydroxy-2-methylbenzamide.




15 The title compound was prepared from 3-tert-butyl-5-bromo-6-methylsalicylic acid and 2,4-dichloro-6-trifluoromethylanilin.

¹H-NMR: (CDCl₃, 400 MHz): δ ppm 1.40 (s, 9 H) 2.69 (s, 3 H) 7.15 (s, 1 H) 7.56 (s, 1 H) 7.68 (s, 1 H) 7.76 (s, 1 H) 9.50 (s, 1 H).); HPLC-MS (Method A): m/z = 498, 500, 502 (M+1); R_t = 5.9 min.

87

Example 63 (General procedure (D))

3-Bromo-5-tert-butyl-6-hydroxy-N-(4-isopropyl-2-trifluoromethyl-phenyl)-2-methyl-benzamide.




The title compound was prepared from 3-tert-butyl-5-bromo-6-methylsalicylic acid
5 and 4-isopropyl-6-trifluoromethylanilin.

$^1\text{H-NMR}$: (CDCl_3 , 400 MHz): δ ppm 1.27 (d, 6 H) 1.41 (s, 9 H) 7.50 (m, 3 H) 7.68 (s, 1 H) 8.20 (m, 1 H) 9.50 (s, 1 H).

10

Example 64 (General procedure (D))

N-(3,5-Bis-trifluoromethyl-phenyl)-3-fluoro-5-trifluoromethyl-benzamide.




15

The title compound was prepared from 3-fluoro-5-trifluoromethyl-benzoic acid and
3,5-Bis-trifluoromethylanilin.

$^1\text{H NMR}$ ($\text{DMSO}-d_6$): δ ppm 7.88 (m, 1 H) 8.04 (d, 1 H) 8.15 (d, 1 H) 8.22 (m, 1 H)
20 8.48 (m, 2 H) 11.04 (s, 1 H); HPLC-MS (Method A): m/z = 420 ($\text{M}+1$); R_t = 5.5 min.

Example 65 (General procedure (D))

3-Fluoro-N-(4-nitro-3-trifluoromethyl-phenyl)-5-trifluoromethyl-benzamide.




5 The title compound was prepared from 3-fluoro-5-trifluoromethyl-benzoic acid and 4-nitro-3-trifluoromethylanilin.

^1H NMR (DMSO- d_6): δ ppm 8.05 (d, 1 H) 8.16 (d, 1 H) 8.21 (s, 1 H) 8.32 (m, 2 H) 8.43 (d, J =1.88 Hz, 1 H) 11.18 (s, 1 H); HPLC-MS (Method A): m/z = 397 (M+1); R_t = 5.0 min.

Example 66 (General procedure (D))

N-(3,5-Bis-trifluoromethyl-phenyl)-3-fluoro-4-trifluoromethyl-benzamide.




15 The title compound was prepared from 3-fluoro-4-trifluoromethylbenzoic acid and 3,5-Bis-trifluoromethylanilin.

^1H NMR (DMSO- d_6): δ ppm 7.77 (m, 1 H) 7.87 (m, 1 H) 8.29 (m, 2 H) 8.49 (m, 2 H) 11.02 (s, 1 H); HPLC-MS (Method A): m/z = 420 (M+1); R_t = 5.4 min.

Example 67 (General procedure (D))

4-Fluoro-N-(4-nitro-3-trifluoromethyl-phenyl)-3-trifluoromethyl-benzamide.




- 5 The title compound was prepared from 4-fluoro-3-trifluoromethylbenzoic acid and 4-nitro-3-trifluoromethylanilin.

^1H NMR ($\text{DMSO}-d_6$): δ ppm 7.77 (m, 1 H) 8.29 (s, 1 H) 8.31 (d, $J=2.26$ Hz, 1 H) 8.39 (m, 3 H) 11.15 (m, 1 H); HPLC-MS (Method A): $m/z = 397$ ($M+1$); $R_t = 4.9$ min.

10

Example 68 (General procedure (F))

3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-(2,2-dimethyl-propionyl)-acrylonitrile



15


The title compound was prepared from 2-phenyl-3-formylindole and malonitrile in ethanol using a catalytic amount of piperidine.

90

$^1\text{H-NMR}$: (CDCl_3 , 300 MHz): δ ppm 1.42 (s, 9 H) 1.47 (s, 18 H) 5.90 (s, 1 H) 7.94 (s, 2 H) 8.20 (s, 1 H); HPLC-MS (Method A): m/z = 342 ($\text{M}+1$); R_t = 6.0 min.

Example 69 (General procedure (F))


- 5 2-Acetyl-3-(3,5-di-*tert*-butyl-4-hydroxy-phenyl)-acrylic acid ethyl ester.



This compound is commercially available from Sigma, cat. no; S482102.

Example 70 (General procedure (F))

- 2-(3,5-Dimethyl-4-hydroxy-benzylidene)-malononitrile



10


The title compound was prepared from 3,5-dimethyl-4-hydroxybenzaldehyde and cyanoacetonitrile in ethanol using a catalytic amount of piperidine

- 15 $^1\text{H-NMR}$: (CDCl_3 , 300 MHz): δ ppm 2.30 (s, 6 H) 7.57 (s, 1 H) 7.61 (s, 2 H); HPLC-MS (Method A): m/z = 199 ($\text{M}+1$); R_t = 3.51 min.

91

Example 71 (General procedure (A))

2-(3,5-Dimethyl-4-hydroxy-benzylidene)-malononitrile




This compound is commercially available from Salor cat. No. S13,586-0.

5

Example 72 (General procedure (A))

2,6-Di-tert-butyl-4-nitro-phenol.




This compound is commercially available from Bionet, cat.no: 7L-850.

10

Example 73 (General procedure (A))


2-tert-Butyl-4,6-dinitro-phenol.



This compound is commercially available from Riedel-de-Haën cat. No. 36775.

Example 74 (General procedure (F))

3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-pyridin-2-yl-acrylonitrile.




5

The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and 2-pyridylacetonitrile in 35 % yield.

10 ^1H NMR ($\text{DMSO}-d_6$): δ ppm 1.43 (s, 18 H) 7.39 (dd, $J=6.41, 4.90$ Hz, 1 H) 7.82 (m, $J=8.67, 8.67$ Hz, 2 H) 7.92 (s, 2 H) 8.39 (s, 1 H) 8.64 (d, $J=4.14$ Hz, 1 H); HPLC-MS (Method A): $m/z = 335$ ($M+1$); $R_t = 5.48$ min..

Example 75 (General procedure (F))

15 2-[1-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-ethylidene]-malononitrile.




The title compound was prepared from 3,5-di-tert-butyl-4-hydroxyacetophenone and malononitrile in 10 % yield.

93

$^1\text{H-NMR}$: (CDCl_3 , 300 MHz): δ ppm 1.45 (s, 18 H) 2.62 (s, 3 H) 5.79 (s, 1 H) 7.50 (s, 2 H); HPLC-MS (Method A): m/z = 297 ($M+1$); R_t = 5.12 min.

Example 76 (General procedure (F))

3-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-2-(diethylphosphonate)-propenenitrile.



5


The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and diethyl cyanomethylphosphonate in 7 % yield.

$^1\text{H-NMR}$: (CDCl_3 , 300 MHz): δ ppm 1.40 (t, $J=7.07$ Hz, 6 H) 1.47 (s, 18 H) 4.20 (m, 4 H) 5.88 (s, 1 H) 7.90 (s, 2 H) 7.96 (s, 1 H); HPLC-MS (Method A): m/z = 394 ($M+1$); R_t = 3.8 min.

10

Example 77 (General procedure (F))

3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-(4-nitro-phenyl)-acrylonitrile.



15


The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and 4-nitrophenylacetonitrile in 62 % yield.

^1H NMR ($\text{DMSO}-d_6$): δ ppm 1.43 (s, 18 H) 7.91 (s, 1 H) 7.95 (s, 2 H) 8.00 (d, $J=8.67$ Hz, 2 H) 8.24 (s, 1 H) 8.33 (d, $J=8.67$ Hz, 2 H); HPLC-MS (Method A): m/z = 379 (M+1); R_t = 5.7 min.

5

Example 78 (General procedure (F))

3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-pyridin-4-yl-acrylonitrile.




The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and
10 2-pyridylacetonitrile in 75 % yield.

^1H NMR ($\text{DMSO}-d_6$): δ ppm 1.43 (s, 18 H) 7.71 (d, $J=6.03$ Hz, 2 H) 8.27 (s, 1 H)
8.65 (d, $J=6.03$ Hz, 2 H); HPLC-MS (Method A): m/z = 335 (M+1); R_t = 3.7 min.

15

Example 79 (General procedure (F))

2-(3,5-Bis-trifluoromethyl-phenyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile.




95

The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and 3,5-bis-trifluoromethyl-phenylacetonitrile in 20 % yield

- 5 ^1H NMR ($\text{DMSO}-d_6$): ppm 1.51 (m, 18 H) 5.78 (s, 1 H) 7.57 (s, 1 H) 7.85 (s, 1 H) 7.86 (s, 2 H) 8.07 (s, 1 H).

Example 80 (General procedure (F))

- 10 3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-(4-trifluoromethoxy-phenyl)-acrylonitrile.




The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and 4-trifluoromethoxy-phenylacetonitrile in 10 % yield

15

- ^1H NMR ($\text{DMSO}-d_6$): δ ppm 1.49 (s, 18 H) 5.68 (s, 1 H) 7.27 (d, 2 H) 7.45 (s, 1 H) 7.68 (d, $J=9.04$ Hz, 2 H) 7.81 (s, 2 H); HPLC-MS (Method A): $m/z = 418$ ($M+1$); $R_t = 6.2$ min.

Example 81 (General procedure (F))

- 3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-(4-trifluoromethyl-phenyl)-acrylonitrile.




20

The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and 4-trifluoromethyl-phenylacetonitrile in 31 % yield

^1H NMR ($\text{DMSO}-d_6$): δ ppm 1.43 (s, 18 H) 7.85 (d, $J=8.29$ Hz, 2 H) 7.92 (s, 2 H)
5 7.94 (d, 2 H) 8.15 (s, 1 H).

Example 82 (General procedure (F))

2-Cyano-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-but-2-enoic acid ethyl ester.




10 The title compound was prepared from 3,5-di-tert-butyl-4-hydroxyacetophenone and ethy cyanoacetic acid in 19 % yield.

^1H NMR ($\text{DMSO}-d_6$): δ ppm 1.27 (t, 3 H) 1.39 (s, 18 H) 2.62 (s, 3 H) 4.24 (q, 2 H)
15 7.37 (s, 2 H) 7.62 (s, 1 H); HPLC-MS (Method A): m/z = 344 ($M+1$); R_t = 5.4 min.

Example 83 (General procedure (F))

N-(4-Chloro-phenyl)-2-cyano-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylamide.




The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and 4'-chloro-2-cyanoacetanilide in 53 % yield

- 5 ^1H NMR ($\text{DMSO}-d_6$): δ ppm 1.42 (s, 18 H) 7.42 (d, $J=9.04$ Hz, 2 H) 7.70 (d, $J=8.67$ Hz, 2 H) 7.91 (s, 2 H) 8.09 (s, 1 H) 8.21 (s, 1 H) 10.32 (s, 1 H); HPLC-MS (Method A): m/z = 412 ($M+1$); R_t = 5.1 min.

Example 84 (General procedure (F))

- 10 (E)-3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-methanesulfonyl-acrylonitrile




Step A: The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and methanesulfonylacetonitrile in 35 % yield.

- 15 ^1H NMR (CDCl_3): δ 1.47 (s, 18 H) 3.18 (s, 3 H) 6.03 (s, 1 H) 7.86 (s, 2 H) 8.04 (s, 1 H); HPLC-MS (Method A): m/z = 358 ($M+\text{Na}$); R_t = 4.79 min.

- 20 **Example 85** (General procedure (F))

(E)-2-(4-Chloro-benzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile




Step A: The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and 4-chlorophenylsulfonylacetonitrile in 72 % yield

5

^1H NMR (CDCl_3): δ 1.45 (s, 18 H) 6.01 (s, 1 H) 7.56 (d, $J=8.59$ Hz, 2 H) 7.83 (s, 2 H) 7.94 (d, $J=8.59$ Hz, 2 H) 8.12 (s, 1 H); HPLC-MS (Method A): m/z = 432 ($M+1$); R_t = 4.88 min.

10 **Example 86** (General procedure (F))

(E)-3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-(4-fluoro-benzenesulfonyl)-acrylonitrile




15 **Step A:** The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and 4-fluoronitrophenylsulfonylacetonitrile in 37 % yield

^1H NMR ($\text{DMSO}-d_6$): δ ppm 1.39 (m, 18 H) 7.58 (dd, $J=8.84$ Hz, 2 H) 7.95 (s, 2 H) 8.08 (dd, $J=9.10, 5.05$ Hz, 2 H) 8.44 (s, 1 H) 8.46 (s, 1 H).

20

Example 87 (General procedure (F))

(E)-2-Benzenesulfonyl-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile



5


Step A: The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and phenylsulfonylacetonitrile in 61 % yield

¹H NMR (DMSO-*d*₆): δ ppm 1.39 (s, 18 H) 7.76 (m, 3 H) 7.95 (s, 2 H) 8.00 (d, *J*=7.16 Hz, 2 H) 8.44 (s, 2 H); HPLC-MS (Method #): *m/z* = 399 (M+1); *R*_t = 5.5 min.

10

Example 88 (General procedure (F))

(E)-3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-(propane-2-sulfonyl)-acrylonitrile



15


Step A: The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and propane-2-sulphonylacetonitrile in 34 % yield

100

^1H NMR (DMSO- d_6): δ ppm 1.32 (d, $J=6.78$ Hz, 6 H) 1.41 (s, 18 H) 3.56 (m, 1 H) 7.98 (s, 2 H) 8.16 (s, 1 H) 8.41 (s, 1 H); HPLC-MS (Method A): m/z = 464 ($M+1$); R_t = 5.0 min.

5 **Example 89** (General procedure (F))

3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-(2,5-dichloro-benzenesulfonyl)-acrylonitrile




10 Step A: The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and 2,5-dichlorophenylsulfonylacetonitrile in 68 % yield.

15 ^1H NMR (DMSO- d_6): δ ppm 1.39 (s, 18 H) 7.82 (d, $J=8.29$ Hz, 1 H) 7.93 (dd, 1 H) 8.00 (s, 2 H) 8.16 (d, $J=2.26$ Hz, 1 H) 8.50 (s, 1 H) 8.58 (m, 1 H); HPLC-MS (Method A): m/z = 465, 467 ($M+1$); R_t = 6.0 min.

Example 90 (General procedure (F))

3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-(2,4-dichloro-benzenesulfonyl)-acrylonitrile




Step A: The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and 3,5-dichlorophenylsulfonylacetonitrile in 68 % yield.

- 5 ^1H NMR ($\text{DMSO}-d_6$): δ ppm 1.39 (s, 18 H) 7.82 (dd, $J=8.48, 2.07$ Hz, 1 H) 8.01 (m, 3 H) 8.21 (d, $J=8.67$ Hz, 1 H) 8.48 (s, 1 H) 8.55 (s, 1 H); HPLC-MS (Method A): $m/z = 467$ (M+1); $R_t = 6.1$ min.

Example 91 (General procedure (F))

- 10 3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-2-(hexane-1-sulfonyl)-acrylonitrile.



Step A: The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and hexane-1-sulfonylacetonitrile in 68 % yield


15

^1H NMR ($\text{DMSO}-d_6$): δ ^1H NMR (400 MHz, $\text{DMSO}-D_6$) \square ppm 0.85 (m, 3 H) 1.26 (m, 4 H) 1.40 (m, 2 H) 1.40 (s, 18 H) 1.69 (m, 2 H) 3.40 (m, 2 H) 7.95 (s, 2 H) 8.17 (s, 1 H) 8.40 (s, 1 H); HPLC-MS (Method A): $m/z = 407$ (M+1); $R_t = 6.4$ min.

20

Example 92 (General procedure (F))

2-(4-Bromo-benzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile



Step A: The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and 4-bromophenylsulfonylacetonitrile in 53 % yield.


5

^1H NMR (DMSO- d_6): δ ppm 1.38 (s, 18 H) 7.93 (d, $J=4.52$ Hz, 6 H) 8.41 (s, 1 H) 8.46 (m, 1 H); HPLC-MS (Method A): m/z = 475, 477 ($M+1$); R_t = 5.7 min.

10

Example 93 (General procedure (F))

2-(3-Bromo-benzenesulfonyl)-3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-acrylonitrile




15 **Step A:** The title compound was prepared from 3,5-di-tert-butyl-4-hydroxybenzaldehyde and 3-bromophenylsulfonylacetonitrile in 53 % yield.

20 ^1H NMR (DMSO- d_6): δ ppm 1.39 (s, 18 H) 7.69 (t, $J=7.91$ Hz, 1 H) 7.96 (s, 2 H) 8.02 (t, $J=6.97$ Hz, 2 H) 8.15 (d, $J=1.88$ Hz, 1 H) 8.47 (s, 1 H) 8.53 (s, 1 H); HPLC-MS (Method A): m/z = 475, 477 ($M+1$); R_t = 5.7 min.

Example 94 (General procedure (D))

5-Bromo-3-tert-butyl-N-(2-chloro-4-cyanophenyl)-2-hydroxybenzamide.




The title compound was prepared from 5-bromo-3-tert-butyl-2-hydroxybenzoic acid
5 and 2-chloro-4-cyanoanilin.

¹H-NMR: (DMSO-*d*₆, 400 MHz): δ ppm 1.48 (s, 9 H) 7.51 (d, 1 H) 7.78 (d, 1 H) 7.92 (dd, 1 H) 8.19 (d, 1H) 8.22 (d, 1 H) 10.88 (s, 1 H) 12.95 (s, 1H); HPLC-MS (Method A): *m/z* = 408 (M⁺); R_t = 5.8 min.

10

Example 95 (General procedure (D))

5-Bromo-3-tert-butyl-N-(4-cyanophenyl)-2-hydroxybenzamide.




The title compound was prepared from 5-bromo-3-tert-butyl-2-hydroxybenzoic acid
15 and 4-cyanoanilin.

¹H-NMR: (DMSO-*d*₆, 400 MHz): δ ppm 1.39 (s, 9 H) 7.49 (d, 1 H) 7.89 (m, 4 H) 8.19 (d, 1 H) 10.80 (s, 1 H) 12.83 (s, 1H); HPLC-MS (Method A): *m/z* = 374 (M+1); R_t = 5.7 min.

Example 96 (General procedure (D))

3-Bromo-5-tert-butyl-6-hydroxy-2-methyl-N-(2-trifluoromethylphenyl)benzamide.




The title compound was prepared from 5-bromo-3-tert-butyl-6-methylsalicylic acid
5 and 2-trifluoromethylanilin.

$^1\text{H-NMR}$: (CDCl_3 , 400 MHz): δ ppm 1.40 (s, 9 H) 2.57 (s, 3 H) 7.33 (dd, 1 H) 7.55 (s, 1 H) 7.65 (dd, 1 H) 7.69 (d, 1 H) 7.76 (br.s, 1H), 8.38 (d, 1 H) 9.45 (br.s, 1 H).

Example 97 (General procedure (G))

10 2-(2-Bromo-1H-indol-3-ylmethylene)malononitrile




The title compound was prepared from 2-bromo-3-formylindol and malonitrile in ethanol using a catalytic amount of piperidine.

15 $^1\text{H NMR}$ ($\text{DMSO}-d_6$): δ ppm 7.32 (m, 2 H) 7.49 (d, 1 H) 8.07 (m, 2 H) 13.75 (s, 1 H);
HPLC-MS (Method A): m/z = 273 ($M+1$); R_t = 3.60 min.

Example 98 (General procedure (G))

2-(7-Bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile




The title compound was prepared from 7-bromo-2-methyl-3-formylindol and malonitrile in ethanol using a catalytic amount of piperidine.

- 5 ^1H NMR ($\text{DMSO}-d_6$): δ ppm 2.66 (s, 3 H) 7.18 (dd, 1 H) 7.48 (d, 1 H) 8.02 (d, 1 H) 8.37 (s, 1 H) 12.73 (br.s, 1 H)

Example 99(General procedure (G))

2-(5-Bromo-2-methyl-1H-indol-3-ylmethylene)malononitrile



- 10 The title compound was prepared from 5-bromo-2-methyl-3-formylindol and malonitrile in ethanol using a catalytic amount of piperidine.

^1H NMR ($\text{DMSO}-d_6$): δ ppm 2.62 (s, 3 H) 7.60 (m, 2 H) 8.28 (s, 1 H) 8.31 (s, 1 H) 12.90 (br.s, 1 H).

15

PHARMACOLOGICAL METHODS

Assay (I): Glucose utilisation in a human hepatocytes cell line (HEP-G2 cells)

Assay description:

The assay measures indirectly the activity of the respiratory chain in HEP-G2 cells by using D-(3-³H(N))-glucose. The ³H-proton will first be released during the metabolism of glucose where it will be incorporated into water. The water is thereafter separated from the D-(3-³H(N))-glucose by evaporation. Finally, the radioactivity in the water is determined using a Topcounter.

Method:

HEP-G2 cells obtained from ATCC (Maryland, USA), are cultured in assay medium (MEM medium) with the following addition 1x non-essential amino acids (M7145, 2 mM glutamine, 100 units/ml penicillin and streptomycin, 0.0075% sodium bicarbonate, 1 mM sodium pyruvate and 0.5% BSA (Bovine Serum Albumin, Sigma Missouri, USA)) at 37°C and 5% CO₂. All media are obtained by Gibco (Life Technologies, Maryland, USA) where not otherwise mentioned.

At day zero the cells are harvested using trypsin-EDTA and washed in assay medium using centrifugation. The cells are plated into single StripPlates wells (Corning B.V. Life Sciences, The Netherlands) that are placed into 24-well plates (Corning B.V. Life Sciences, The Netherlands) with a concentration of 2×10^4 cells/100 µl/well. The cells are then incubated at 37°C and 5% CO₂ overnight.

The next day the compounds to be tested are diluted in DMSO (Sigma, Missouri, USA) to 100 times final concentration. They are then diluted to a final concentration in assay medium containing 10 µCi/ml D-(3-³H(N))-glucose (PerkinElmer Life Sciences Inc., Boston, USA). The medium is removed from the cells and 200 µl of the compound dilutions are added in duplicates. The cells are then incubated for another 3 hours at 37°C and 5% CO₂. Finally the cells are lysed by adding 50 µl 10% TCA (trichloroacetic acid). 300 µl of sterile water is then added to the 24-wells that surrounds the StripPlate wells. The plate is sealed with Top-seal-tape (Packard, PerkinElmer Life Sciences Inc., Boston, USA) and the plate is incubated in a heating cupboard at 50°C to equilibrium the radioactive water formed in the respiratory chain into the water in the 24-well plate by evaporate. The plates incubate for 8 hours where the heating cupboard is turned off. The top seal is removed when the samples have reached room temperature. One ml scintillation liquid (Packard Microscint, PerkinElmer Life Sciences Inc., Boston, USA) is added to all the samples and the radioactivity is determined using a Topcounter (Packard, PerkinElmer Life Sciences Inc., Boston, USA). Non-specific activity is determined by evaporating 200 µl of the dilution medium containing the D-

(3-³H(N))-glucose into 300 µl sterile water, and total radioactivity is determined by counting 5 µl assay medium with 10 µCi/ml D-(3-³H(N))-glucose.

Calculations:

The cpm (counts per minute) representing the non-specific radioactivity in the D-(3-³H(N))-glucose is subtracted from all incubated values. Then mean basal value (samples without any compound added) is subtracted from the values of all stimulated samples (samples added different concentrations of the different test compounds). All these calculations are done using GraphPad Prism 3.0 (GraphPad software, Inc.). The maximal stimulation caused by the test compounds is calculated in percentage of maximal stimulation caused by either DNP or FCCP. If a test compound represents a saturated maximal stimulation that is less than 75% of maximal DNP/FCCP stimulation, that is, E_{\max} for the test compound is less than 75% of the E_{\max} for DNP or FCCP in Assay (I), it is considered as a partial stimulator, see figure 1, wherein the curve for SF6847 is compared to the curve for a partial stimulator according to the present invention. An E_{\max} of less than 75% of the E_{\max} for DNP or FCCP may signify that a saturation of the uncoupling process is taking place.

When calculating the concentration-response curve the maximal glucose utilisation stimulated by FCCP or DNP (subtracted non-specific and basal values) is converted to 100% and all the other values are expressed in percentage of this value. Using these percentage values and the compound concentration a concentration-response curve is calculated using sigmoidal dose-response (variable slope) equation (all the calculations are done by GraphPad Prism 3.0 (GraphPad software, Inc.));

Equation 1:

$$Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{((\text{LogEC}_{50} - X) \cdot \text{slope})})$$

25

X is the logarithm of the molar concentration of the test compound.

Y is the degree of stimulation caused by the compound measured as a percentage of the maximal stimulation achieved by use of FCCP or DNP.

Y starts at Bottom which is the value for the stimulation caused by the lowest concentration of the test compound and goes to Top which is the value for the stimulation caused by the highest concentration of the test compound and the curve for Y as a function of X has a sigmoid shape. The concentration of the test compound that stimulates the glucose utilisation with 50% is defined as EC_{50} . From the calculated EC_{50} value, new concentrations of the compound corresponding to $3 \times EC_{50}$, $2 \times EC_{50}$, $EC_{50}/2$, $EC_{50}/3$ and control are tested in Assay

30

(I). The results achieved with these concentrations are used to determine the slope in this area using the following equation:

Equation 2:

$$(Y_2 - Y_0) / (Y_1 - Y_0) = X^n$$

where Y_0 is the degree of stimulation measured as counts per minute (cpm) in Assay (I) in control samples without added test compound, Y_1 is the degree of stimulation measured as cpm in Assay (I) with added test compound in a concentration of either $EC_{50}/2$ or $EC_{50}/3$, and Y_2 is the degree of stimulation measured as cpm in Assay (I) with added test compound in concentration of either $2xEC_{50}$ or $3xEC_{50}$, X is either 2 or 3, and n is the slope.

The equation should be understood such that when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/2$, then Y_2 is the degree of stimulation with added test compound in concentration of $2xEC_{50}$, and X is 2, and when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/3$, then Y_2 is the degree of stimulation with added test compound in a concentration of $3xEC_{50}$, and X is 3.

The slope calculated by this equation is defined as the change in response divided with the change in test compound concentration around the EC_{50} value of the compound. If this equation is high then a small change in test compound concentration cause a great change in the response, like when using DNP or FCCP. If the slope is close to unity then a small change in test compound concentration cause a small change in the response, a relation that can be used to determine that the test compound has a broader safety-window than DNP or FCCP. This slope may thus be used to describe safe chemical uncouplers for use according to the present invention (see figure 2).

Another way of describing safe chemical uncouplers is that no sign of toxicity (defined as a significant drop in glucose utilisation in Assay (I)) may occur within a ten fold increase of the concentration of the compound needed for achieving E_{max} . This characteristic will for the purpose of this application be designated a "long E_{max} ", meaning that for compounds with a long E_{max} , the glucose utilisation does not decrease for concentrations ranging from the concentration of the compound needed for achieving E_{max} to 10 times this concentration. Compounds with a long E_{max} may be regarded as safe chemical uncouplers. The following Table 1 shows the data from Assay (I) for the compounds of the examples.

Equation 1:

$$Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{((\text{LogEC}_{50} - X) \cdot \text{slope})})$$

X is the logarithm of the molar concentration of the test compound.

Y is the degree of stimulation caused by the compound measured as a percentage of the maximal stimulation achieved by use of FCCP or DNP.

Y starts at Bottom which is the value for the stimulation caused by the lowest concentration of the test compound and goes to Top which is the value for the stimulation caused by the highest concentration of the test compound and the curve for Y as a function of X has a sigmoid shape. The concentration of the test compound that stimulates the glucose utilisation with 50% is defined as EC_{50} . From the calculated EC_{50} value, new concentrations of the compound corresponding to $3xEC_{50}$, $2x EC_{50}$, $EC_{50}/2$, $EC_{50}/3$ and control are tested in Assay (I). The results achieved with these concentrations are used to determine the slope in this area using the following equation:

Equation 2:

$$(Y_2 - Y_0) / (Y_1 - Y_0) = X^n$$

15

where Y_0 is the degree of stimulation measured as counts per minute (cpm) in Assay (I) in control samples without added test compound, Y_1 is the degree of stimulation measured as cpm in Assay (I) with added test compound in a concentration of either $EC_{50}/2$ or $EC_{50}/3$, and Y_2 is the degree of stimulation measured as cpm in Assay (I) with added test compound in concentration of either $2xEC_{50}$ or $3xEC_{50}$, X is either 2 or 3, and n is the slope.

The equation should be understood such that when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/2$, then Y_2 is the degree of stimulation with added test compound in concentration of $2xEC_{50}$, and X is 2, and when Y_1 is the degree of stimulation with added test compound in a concentration of $EC_{50}/3$, then Y_2 is the degree of stimulation with added test compound in a concentration of $3xEC_{50}$, and X is 3.

The slope calculated by this equation is defined as the change in response divided with the change in test compound concentration around the EC_{50} value of the compound. If this equation is high then a small change in test compound concentration cause a great change in the response, like when using DNP or FCCP. If the slope is close to unity then a small change in test compound concentration cause a small change in the response, a relation that can be used to determine that the test compound has a broader safety-window than DNP or FCCP. This slope may thus be used to describe safe chemical uncouplers for use according to the present invention (see figure 2).

Another way of describing safe chemical uncouplers is that no sign of toxicity (defined as a significant drop in glucose utilisation in Assay (I)) may occur within a ten fold in-

crease of the concentration of the compound needed for achieving E_{\max} . This characteristic will for the purpose of this application be designated a "long E_{\max} ", meaning that for compounds with a long E_{\max} , the glucose utilisation does not decrease for concentrations ranging from the concentration of the compound needed for achieving E_{\max} to 10 times this concentration. Compounds with a long E_{\max} may be regarded as safe chemical uncouplers

5 The following Table 1 shows the data from Assay (I) for the compounds of the examples.

111

Table 1

Exempl no.	FSK4 EC ₅₀ (μ M)	FSK4 E _{max} (% of FCCP)	FSK4 Slope (% of FCCP)	Mito State-4	HEP-G2 EC ₅₀ (μ M)	HEP-G2 E _{max} (% of FCCP)	HEP-G2 E _{max} (μ M)	HEP-G2 Slope	HEP-G2 Long E _{max} / Tox
1				Ok	40	45	100	1.5	
2				-	290	35	1000		
3				-	270	75	1000		
4				-	150	70	1000	1.4	
5	0.1	100	115	-	0.06	95	0.3	1.7	Long E _{max} Tox 0.1 mM
6				-	1.6	95	10		
7									
8				-	12	80	100		
9				-	2.3	100	10	3.1	Long E _{max}
10	0.3	80	95	-	0.37	100	3	1.7	Long E _{max}
11	0.3	90	105		0.7	75	3		Tox 0.03 mM
12	0.3	85	170	-	1.2	70	10		Tox 0.03 mM
13	1	85		-	2.9	70	10		Tox 0.03 mM
14	0.2	100	135	-	1.1	100	10		Tox 0.01 mM
15	2	65	60	-	0.7	100	3		Long E _{max}
16	30	45		-	11	100	100	2.3	
17				-	6	45	30		Tox 0.1 mM
18	6	100	50	-	0.6	80	3		Long E _{max}
19	1.1	55		-	7	100	100	1.5	
20	26	90	80	-	50	55	300	1	
21									
22				-	91	100	1000		

112

Exempl no.	FSK4 EC ₅₀ (μ M)	FSK4 E _{max} (% of FCCP)	FSK4 Slope (% of FCCP)	Mito State-4	HEP-G2 EC ₅₀ (μ M)	HEP-G2 E _{max} (% of FCCP)	HEP-G2 E _{max} (μ M)	HEP-G2 Slope	HEP-G2 Long E _{max} / Tox
23				-	1.75	117	30		Long E _{max}
24				-	42	65	100	2.3	Long E _{max}
25	0.01	110	120	Ok	0.48	100	10	1.3	Long E _{max}
26	90	95	120	Ok	225	100	500	3	
27	1	100	100	Ok	3	100	30	2.2	Long E _{max}
28				-	35.5	35	300		
29				-	13	65	30		Long E _{max}
30	50	100	85	Ok	19.5	60	100		Long E _{max}
31				-	300	0			
32	> 100	> 15		-	7	60	100		
33									
34	0.4	90	95	Ok	1.4	80	10		Long E _{max}
35	5	50	90	-					
36	6.35	76	65	-					
37	0.03	110	95	Ok	0.035	100	1		Long E _{max}
38				-	3.35	105	30		Long E _{max}
39				-	6	55	10		Long E _{max}
40				Ok	0.58	105	3		Long E _{max}
41				-	4	103	30		Long E _{max}
42	1.1	75	120	-	3.3	89	10		Long E _{max}
43	0.3	80	75	-	0.85	95	3		Long E _{max}
44				-	2	94	30		Long E _{max}
44	3.6	90	55	-	1.4	95	10		Long E _{max}
45				-	0.6	96	3		Long E _{max}
46				-	3	103	10		Long E _{max}
47	1	90	95	-	0.7	75	10		Tox 0.1 mM
48	2.8	85	90	-	3.5	95	10		Long E _{max} Tox

113

Example no.	FSK4 EC ₅₀ (μM)	FSK4 E _{max} (% of FCCP)	FSK4 Slope (% of FCCP)	Mito State-4	HEP-G2 EC ₅₀ (μM)	HEP-G2 E _{max} (% of FCCP)	HEP-G2 E _{max} (μM)	HEP-G2 Slope	HEP-G2 Long E _{max} / Tox
49	0.3	95	95	-	0.95	105	3		0.1mM
50	<0.03	75	90	Ok	0.03	82	0.1		Long E _{max}
51	0.3	105	90	-	0.4	100	3		Long E _{max}
52	2.5	75	120	-	2.4	95	10		Long E _{max}
53	15	95	70	-	4.15	90	10		Long E _{max}
54	0.3	80	95	-	0.52	90	3		Long E _{max}
55	0.3	100	85	-	0.36	99	1		Long E _{max}
56	8	105	90	Ok	6.6	100	100		
57				-	0.31	90	10		Long E _{max}
58	<0.03	100	105	Ok	0.03	100	0.1		Long E _{max}
59	0.03	100	125	-	0.11	110	10		Long E _{max}
60	0.3	105	120	-	0.07	90	0.3		Long E _{max}
61	1.1	105	115	-	0.87	105	10		Long E _{max}
62	1.2	85	130	-	2.3	115	30		Long E _{max}
63	19	55	90	-	14	90	100		
64				-	2.6	105	10		Long E _{max}
65				-	5.3	100	10		Long E _{max}
66				-	4.3	95	10		Long E _{max}
67				-	5.9	85	30		Long E _{max}
69	9	40	110	-	100	58	300		Tox 1 mM
70	7	180	85	-	32	112	300		
71				-	75	105	1000		
72				Ok	13	100	100		
73	7	100	170	-	7.3	70	300		
74	15	120	90	-	16	80	100		
75	0.7	75	90	Ok	0.36	120	30		Tox 0.3 mM
76	3.2	150	85	-	11	90	30		
77	1	110	70	Ok	0.31	100	3		Long E _{max}

114

Example no.	FSK4 EC ₅₀ (μ M)	FSK4 E _{max} (% of FCCP)	FSK4 Slope (% of FCCP)	Mito State-4	HEP-G2 EC ₅₀ (μ M)	HEP-G2 E _{max} (% of FCCP)	HEP-G2 E _{max} (μ M)	HEP-G2 Slope	HEP-G2 Long E _{max} / Tox
78				-	2.9	80	10		Long E _{max}
79				-	1	80	3		Long E _{max} Tox 0.3 mM
80	18	100	70	-	8	80	100		Tox 0.3 mM
81	7	140	75	-	7	130	100		
82	11	90	90	-	10	100	30		Long E _{max}
83	1.1	120	85	-					
84	1.4		100						
85	0.8		49						
86	1.0		31						
87	0.7		41						
88	0.5		103						
89	0.5		84						
90	0.6		86						
91	3.8		47						
92	1		48						
93	0.1								
94	0.1	90	85	-	-	-	-		
95	-	-	-	-	-	-	-		
96	20	40	-	-	-	-	-		
97	1.5	55	45	-	-	-	-		
98	6.6	105	65	-	-	-	-		
99	1.7	40	-	-	-	-	-		

Assay (II) - The effect of chemical uncouplers on mitochondrial respiration using isolated mitochondria.

5 Assay description:

This assay is used to investigate if the increase in glucose utilisation caused by the test compounds observed in the glucose utilisation assay is due to an increase in the respiration of the mitochondria. This is done by measuring oxygen consumption in isolated mitochondria.

- 10 A Clark oxygen electrode is used to determine the oxygen consumption. The isolated mitochondria are added to medium containing oxygen and nutrients (e.g. Succinate) and the rate of oxygen consumptions is measured, when stabilized a small amount of ADP is added to increase the respiration and an increase in the rate of oxygen consumption is measured. When the rate of oxygen consumption again has stabilized the test compound is
- 15 added and a further increase in oxygen consumption is seen. This experiment is done with and without the addition of oligomycin which is an inhibitor of the ATP-synthase. Finally, the test compound is examined without adding ADP. If the test compound stimulates the rate of oxygen consumption in all setups, it is regarded as a chemical uncoupler.

Assay (III): Identification of chemical uncouplers (full or partial chemical uncouplers) that increase energy expenditure *in vivo*

- 20 The effect of the chemical uncouplers (full or partial agonists) on energy expenditure (oxygen consumption) *in vivo* is determined by indirect calorimetry. Briefly, animals are placed in air-tight chambers. Air is continuously led to and from the chambers. The gas concentrations of oxygen (O₂) and carbondioxide (CO₂) in the air led to and from the chambers (inlet and outlet
- 25 air) are recorded and the consumption of O₂ and the production of CO₂ are calculated. Based on the amount of O₂ consumed and CO₂ produced, energy expenditure is calculated. Compounds which at a given dose increase whole body energy expenditure without obvious deleterious effects are deemed to be chemical uncouplers that increase energy expenditure.

Correlation between in vitro slope and in vivo safety

We have further shown that compounds that exhibit the preferred slopes *in vitro* in Assay (1) equation 2 also have a correspondingly low slope in the linear part of the dose-response curve in the *in vivo* EE assay (Assay III) compared to DNP.

- 5 Further more when the maximal tolerable dose (MTD) were determined for the compounds the relationship still exist; compounds with low *in vitro* slopes have a high safety window (defined as MTD/dose that activates a 20% increase in the EE *in vivo*).

10 **Assay (IV): Glucose utilisation in FSK-4 cells**

Assay description:

- The assay measures indirectly the activity of the respiratory chain in FSK-4 cells by using D-(6-³H(N))-glucose. The ³H-proton will first be released in the TCA cyclus and transported to the respiratory chain where it will be incorporated into water. The water is thereafter
15 separated from the D-(6-³H(N))-glucose by evaporation. Finally, the radioactivity in the water is determined using a Topcounter.

Method:

- FSK-4 cells obtained from ATCC (Maryland, USA), are cultured in growth medium (McCoy's medium with the following addition 100 units/ml penicillin and streptomycin and 10
20 % FCS (fetal calf serum)) at 37°C and 5% CO₂. All media are obtained by Gibco (Life Technologies, Maryland, USA) where not otherwise mentioned.

- At day zero the cells are harvested using trypsin-EDTA and washed in assay medium (MEM medium with the following addition 1x non-essential amino acids (M7145, 2 mM glutamin, 100 units/ml penicillin and streptomycin, 0.0075% sodium bicarbonate, 1 mM so-
25 dium pyrovalate and 2 % horse serum) using centrifugation. The cells are plated into single StripPlates wells (Corning B.V.Life Sciences, The Netherlands) that are placed into 24-well plates (Corning B.V.Life Sciences, The Netherlands) with a concentration of 1,5x10⁴ cells/100 µl assay medium/well. The cells are then incubated at 37°C and 5% CO₂ overnight.

- The next day the compounds to be tested are diluted to different concentrations in
30 DMSO (Sigma, Missouri, USA) to 100 times final concentration. They are then diluted to a final concentration in assay medium containing 10 µCi/ml D-(6-³H(N))-glucose (PerkinElmer Life Sciences Inc., Boston, USA). The medium is removed from the cells and 200 µl of the compound dilutions are added in duplicates. The cells are then incubated for another 24

hours at 37°C and 5% CO₂. Finally the cells are lysed by adding 50 µl 10% TCA (trichloroacetic acid). 300 µl of sterile water is then added to the 24-wells that surrounds the StripPlate wells. The plate is sealed with Top-seal-tape (Packard, PerkinElmer Life Sciences Inc., Boston, USA) and the plate is incubated in a heating cupboard at 50°C to equilibrium the radioactive water formed in the respiratory chain into the water in the 24-well plate by evaporate. The plates incubate for 8 hours where the heating cupboard is turned off. The top seal is removed when the samples have reached room temperature. One ml scintillation liquid (Packard Microscient, PerkinElmer Life Sciences Inc., Boston, USA) is added to all the samples and the radioactivity is determined using a Topcounter (Packard, PerkinElmer Life Sciences Inc., Boston, USA). Non-specific activity is determined by evaporating 200 µl of the dilution medium containing the D-(6-³H(N))-glucose into 300 µl sterile water, and total radioactivity is determined by counting 5 µl assay medium with 10 µCi/ml D-(6-³H(N))-glucose.

Calculations:

All calculations are done using GraphPad Prism 3.0 (GraphPad software, Inc.) From concentration-response curves the half maximal concentration (EC₅₀) and maximal efficacy (E_{max}) are calculated using equation 1.

Equation 1:

$$Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / (1 + 10^{((\text{LogEC}_{50} - X) * \text{slope})})$$

X is the logarithm of the molar concentration of the test compound.

Y is the degree of stimulation caused by the compound measured as percentage of the basal stimulation.

Y starts at Bottom which is the value for the stimulation caused by the lowest concentration of the test compound and goes to Top which is the value for the stimulation caused by the highest concentration of the test compound and the curve for Y as a function of X has a sigmoid shape.

The calculated EC₅₀ value is then used to determine the concentrations used in a study where the Hill slope is calculated. In the Hill slope study concentrations between 0.05 to 10 times EC₅₀ are used.

From the double logarithmic plot of the increase in glucose utilisation and the compound concentration the Hill slope is calculated accordingly to equation 2.

Equation 2:

$$\frac{V}{V_{\max}} = \frac{[X]^n}{K_H + [X]^n} \quad \longleftrightarrow$$

$$\frac{V_{\max}}{V} = \frac{K_H}{[X]^n} + 1 \quad \longleftrightarrow$$

$$\frac{V_{\max} - V}{V} = \frac{K_H}{[X]^n} \quad \longleftrightarrow$$

$$\text{Log } V_{\max} - \text{Log } V = \text{Log } K_H - n \cdot \text{Log } [X] \quad \longleftrightarrow$$

$$\text{Log } V = \text{Log } V_{\max} - \text{Log } K_H + n \cdot \text{Log } [X]$$

X is the molar concentration of the test compound

15 V is the increase in glucose utilisation

V_{\max} is the theoretic maximal no-limiting increase in glucose utilisation

K_H is the Hill equation constant

n is the Hill slope

20 It is presumed, that the maximal increase in the glucose utilisation (as measured in the FSK-4 glucose utilisation assay) is limited by the capacity of the metabolism. It is furthermore presumed, that the glucose utilisation would reach a much higher degree of stimulation if the metabolism were not the limiting factor (the theoretical maximal stimulation in the FSK-4 glucose utilisation if metabolism were not the limiting factor is denoted V_{\max} in the equation above). Consequently, $V_{\max} - V \approx V_{\max}$, where V is the measured increase in FSK-4 glucose utilisation. Finally, it is assumed that $\text{Log } V_{\max} - \text{Log } K_H$ is a constant.

25